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The brochure “Cancer in Germany” is published jointly every 
two years by the Association of Population-based Cancer 
Registries in Germany (Gesellschaft der epidemiologischen 
Krebsregister in Deutschland e.V., GEKID) and the Robert 
Koch Institute (RKI). This sixth edition has a new design and 
is being published for the first time as part of a series of  
reports within the framework of Federal Health Reporting 
(German abbreviation: GBE). It contains information on the 
total number of new cancer cases in Germany diagnosed 
between 1980 and 2004, and on selected individual cancer 
sites, each of which is succinctly described and clearly pre-
sented (with information on incidence and mortality rates, 
risk factors, trends and survival). The RKI’s current estimates 
are based on data from population-based cancer registries in 
Germany that provide sufficiently complete coverage. The  
estimate for 2004 is 436,500 new cancer cases (230,500 
men, 206,000 women). This means the number of new can-
cer cases was approx. 12,000 higher in 2004 than in 2002, 
when the previous estimate ended. The total number of  
cases among women remained unchanged compared to 
2002. Most of the additional cases in 2004 were men with 
prostate cancer, the most common cancer among men with 
approx. 58,500 cases. As in previous estimates, the most 
common form of cancer among women was breast cancer 
with approx. 57,000 new cases. A total of 208,800 people 
died of cancer in Germany in 2004 compared to 209,900 
in 2002. The survival prospects of patients with prostate 
or breast cancer have improved to such an extent that the 
number of people dying from these cancers is now decreas-
ing. 11,200 men died of prostate cancer and 17,600 women 
of breast cancer in 2004 – which is 200 fewer respectively 
than two years earlier. Information on cancer in children is 
provided by the Children’s Cancer Registry in Mainz in a 
separate section of this brochure.
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such as the average age at onset/diagnosis of the 
disease (calculated as the median of the age distri-
bution) and the relative 5-year survival rates of can-
cer patients. Frequently used terms are explained 
in the glossary at the end of the brochure. 
In future editions, the range of cancer sites 
covered will be successively extended as the qual-
ity of the data available to the cancer registries 
improves.
1 2   Aims and tasks of population-based 
cancer registries 
Population-based (epidemiological) cancer reg-
istries are institutions for the collection, storage, 
processing, analysis and interpretation of data on 
the occurrence and frequency of cancers within 
defined populations (e.g. the inhabitants of a Ger-
man state). 
Data from population-based cancer registries 
are needed as a basis for further research into the 
causes of cancer and for efforts to improve can-
cer care. 
Examples of findings deduced from population-
based cancer registries include:
The prostate, intestines and lungs are the most  ▶
common cancer sites among men.
The incidence of cancer in a given population can 
be measured with the data from population-based 
cancer registries. Cancer incidence is defined as 
the frequency with which newly diagnosed cancer 
cases occur in this population within a year. The 
incidence is broken down according to cancer type, 
the patient's age and gender, and other character-
istics. Reliable information on incidence is indis-
pensable for describing the extent and type of the 
burden that cancer places on a population. 
 For some years now there have been just as  ▶
many cases of lung cancer in Germany among 
women under the age of 40 as among men of 
the same age.
This sixth edition of "Cancer in Germany" has a 
new design and is published for the first time as 
part of the Health Reporting series of the Robert 
Koch Institute (RKI). It is published in this form 
jointly by the Association of Population-based Can-
cer Registries in Germany (GEKID) and the RKI 
every two years. 
This 6th edition covers cancer cases that were 
diagnosed in Germany between 1980 and 2004. 
As a rule, population-based cancer registries need 
about three years from the end of the year of diagno-
sis to the publication of sufficiently complete inci-
dence figures. All cancer cases occurring must be 
reported to the registry in full and all deaths in the 
region matched against the data collected. Only in 
this way can reliable assessments on incidence and 
survival rates be derived from the available data. 
Every year the Federal Cancer Surveillance Unit at 
the Robert Koch Institute receives the data from the 
registries of currently 13 of 16 federal states (Länder) 
and two administrative districts, examines them for 
consistency and completeness and pools them for 
further analysis (see section 2.1). The data from all 
population-based cancer registries in Germany with 
diagnoses up to 2004 were transferred to the RKI in 
the spring of 2007. The only data still missing are 
from Baden-Württemberg, whose cancer registry 
is currently being built up. The available data from 
North Rhine-Westphalia relate only to the adminis-
trative district of Münster. Hesse is represented for 
the first time with data for the Darmstadt admin-
istrative district and extended its cancer registry in 
2007 to cover the whole state. Hence, apart from 
the three exceptions mentioned, complete popula-
tion-based data on cancer cases are available all over 
the country. These data form the basis of the current 
edition of "Cancer in Germany", with estimates of 
new cancer cases up to 2004 (see section 2.2). 
The brochure contains charts and tables on 
all selected cancer sites with information on age-
specific incidence, time trends and the regional 
distribution of incidence and mortality. The text 
sections on the individual cancer sites describe 
the most important risk factors (the correspond-
ing charts and tables directly follow the texts). This 
information is supplemented by further indicators 
1    Preface
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Cancer in Germany6
The data from population-based cancer registries 
make it possible to observe the development (trend) 
of incidence over time. The registries have a senti-
nal function in this field.
Regional differences in the incidence of malig- ▶
nant melanoma of the skin (black skin cancer) 
can be observed within Europe and Germany.
Population-based cancer registries can analyse 
the regional distribution of cancer sites. They also 
have the task of examining observed cancer clus-
ters. More detailed analytical studies are usually 
required to determine the causes of these clusters.
The survival expectations of men with testicular  ▶
cancer have improved decisively over the last 
25 years.
Population-based cancer registries analyse the 
survival periods of all cancer patients without 
selection. Population-based survival rates are an 
extremely important parameter for assessing the 
effectiveness of the health services in their fight 
against cancers.
Predicting the future number of new cancer  ▶
cases is an important aspect of requirements 
planning for the health service.
The population-based cancer registries provide the 
necessary data.
The data from population-based cancer reg-
istries not only serve to describe the incidence of 
cancer in the population, they are also used for sci-
entific research into the causes of cancer and for 
research on healthcare effectiveness. Such studies 
(case-control studies, cohort studies, etc.) follow up 
issues such as:
What are the causes of leukaemia in child- ▶
hood?
Do people in certain occupational groups develop  ▶
lung cancer more frequently than others?
Are diagnosis, therapy and post-initial treat- ▶
ment being carried out according to the latest 
standards?
Population-based cancer registries guarantee 
that all cases of the disease that have occurred in 
a defined population can be taken into account 
for causal research. This largely ensures that the 
results of such studies apply not only to the group 
studied, but also to the entire population. Popula-
tion-based case-control studies and cohort studies 
use data from population-based cancer registries 
for research into the causes and risks of cancer.
Does mammographic screening lead to the dis- ▶
covery of tumours at more favourable stages, 
thus improving survival prospects?
The data from population-based cancer registries 
with complete coverage make it possible to assess 
the effectiveness of preventive and screening pro-
grammes. In this way the data from a population-
based registry can be used to detect differences in 
stage distribution at diagnosis throughout the pop-
ulation. The declining trend in the incidence of 
invasive (fully developed) carcinomas of the cervix 
is a measure of the success of the corresponding 
screening programme. 
The degree of completeness of data ascertain-
ment that has now been reached has also led to fur-
ther progress in the use of the registry data. Here 
are some topical examples: 
a study of oncological care for cancer patients,  ▶
an evaluation of pilot projects on mammo- ▶
graphic screening, quality-assured breast-cancer 
diagnostics and skin-cancer screening,
a study on hormone therapy as a risk factor for  ▶
breast cancer,
cooperation with breast centres in long-term  ▶
follow-up, 
a study on the effectiveness of colonoscopy  ▶
screening.
(For a detailed list see: www.gekid.de).
The evaluation of screening measures will be a 
particular challenge for the population-based 
cancer registries in the coming years. Among 
other things the focus will be on assessing mam-
mographic screening, which is currently being 
introduced nationwide in Germany. The expected 
increase in breast-cancer incidence in the age 
group of 50-to-69-year-old women and a more 
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favourable tumour-stage distribution have been 
documented in regions where mammography 
pilot projects have already been completed. Skin-
cancer screening will probably be introduced 
in 2008 by statutory health insurance as a new 
early-detection measure; its effect can then also 
be reviewed using the data from the cancer reg-
istries.
A longer-term task of the population-based 
cancer registries is examining the effectiveness of 
the recently launched vaccination programme for 
girls aged between 12 and 17 against human papil-
lomavirus (HPV); its aim is to achieve a marked 
reduction in new cases of cervical cancer. 
In order to establish comprehensive health 
monitoring – i.e. an ongoing comparative analy-
sis of cancer in the population – it is not enough 
to run population-based cancer registries only 
in selected regions of the Federal Republic. To 
achieve this objective, comprehensive cancer reg-
istries must be up and running in all states. The 
Federal Cancer Registry Act (1995 to 1999) initi-
ated the development of a network of state cancer 
registries. It also provided a uniform framework 
for the transfer of data to a central institution for 
nationwide evaluation: the Federal Cancer Sur-
veillance Unit at the Robert Koch Institute (RKI). 
Although the states used the broad scope pro-
vided by the law in organizing the regional regis-
tries, the comparability of the collected data and 
their general use for statistical and epidemiologi-
cal purposes is assured because the state laws 
adopted important parts of the Federal Cancer 
Registry Act.
In order to be able to pool information about 
an individual's cancer condition from different 
sources, the data are collected in such a way that 
multiple reports on the same person are recog-
nizable. For research purposes it should be pos-
sible to re-establish a link between the data and 
the person. In order to safeguard patients' privacy 
and their right to control what happens to their 
data, extensive precautions are required to pro-
tect personal data; these are provided by the legal 
framework governing all registries. 
An appropriate evaluation of the data is only 
possible if at least 90% of all new cancer cases 
are registered. The cooperation of all doctors and 
dentists involved in diagnosis, treatment and 
aftercare is therefore crucial to the informational 
value of data from a population-based cancer reg-
istry. Patients are also requested to actively take 
part in cancer registration. 
 
1 3   Current development of cancer regis-
tration in Germany
Population-based cancer registration has devel-
oped very positively in Germany over the last two 
years.
For example, a new state cancer registry law 
was passed in Baden-Württemberg in 2006 pro-
viding for a state-wide cancer registry. Cancer reg-
istration is being introduced there in stages. An 
external project-management company has been 
entrusted with the task. According to the project 
plan, cancer registration will begin in early 2009 
at oncological surgeries and tumour centres. The 
system will be further extended in a second stage. 
In the state of Hesse, too, the cancer registry law 
has been amended; in the process, data acquisition 
on cancer cases was expanded to cover the whole 
federal state at the beginning of 2007.
An important milestone for population-based 
cancer registration has thus been reached in Ger-
many – the registration of cancer cases has now 
been placed on a legal footing all over the country. 
Now the challenge is to quickly implement a com-
plete registration system in the new regions. In 
a few years the estimates on the number of new 
cancer cases in Germany, as used for this edition, 
can then be supplemented with the pooled figures 
from all the state registries.
As a result of the considerable improvement 
in cancer registration in Germany, "Cancer Inci-
dence of Five Continents", a series published by 
IARC (World Health Organization's International 
Agency for Research on Cancer, Lyon, France), is to 
include six further German cancer registries with 
incidence data from 1998 to 2002 in addition to 
the data from the Saarland Cancer Registry, start-
ing with the latest edition (volume IX). 
The efficiency of the cancer registries has 
been further increased since the publication of 
the 5th edition of "Cancer in Germany" in 2006. 
The progress that has been made with registration 
is partially due to the introduction of the compul-
sory reporting of new cancer cases in many Ger-



































Figure 1 3 1
Status of population-based cancer registration in Germany
(Year = beginning of registration)
Population-based cancer Registration
Registry under construction
1 1953 East-Berlin, 1995 all of Berlin
2 1986 Münster administrative district, 2005 all of North Rhine-Westphalia
3 2003 Darmstadt administrative district, 2007 all of Hesse
German Registry of Cancer in Children, covers all of Germany (1980)
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between the registries has also been improved. 
Laws in many states now allow reports relating to 
patients outside the registry area to be forwarded 
to the cancer registry responsible for the patients' 
places of residence. Otherwise, information on 
the treatment of cancer patients outside their own 
state would frequently be lost.
The Association of Population-based Cancer 
Registries in Germany" (Gesellschaft der epide-
miologischen Krebsregister in Deutschland e.V., 
abbreviated to GEKID), whose members include 
not only all the population-based cancer regis-
tries, but also scientists working in the field of 
cancer epidemiology, has been working inten-
sively over the past two years on the harmoniza-
tion and standardization of cancer registration in 
Germany. One result is that the "Manual of Pop-
ulation-based Cancer Registration", which sets 
down the coordinated methodological principles 
of cancer registration in Germany, is being pub-
lished in 2008. Further information on the asso-
ciation is available on the Internet at www.gekid.
de (see appendix).
The public offer for tender of a contract on 
"cancer epidemiology" funded by the organiza-
tion German Cancer Aid in 2007 was especially 
important for population-based cancer registra-
tion in Germany and the scientific use of the col-
lected data. The funding was made conditional 
on the inclusion of population-based cancer reg-
istries. About 40 applications were made to Ger-
man Cancer Aid (Deutsche Krebshilfe e.V.); the 
first projects are expected to be approved and 
launched in 2008.
Coordination and cooperation between popu-
lation-based and clinical cancer registries has also 
developed very positively. For example, the popu-
lation-based cancer registries in Germany and the 
clinical registries recently defined their respective 
core competencies in two keynote papers; they 
reaffirmed their intention to cooperate on improv-
ing the quality and usefulness of the data from 
both forms of registry and avoiding unnecessary 
pressure on those reporting caused by their hav-
ing to repeatedly report the same information.
In order to further improve cancer registra-
tion, the GEKID advocates reducing multiple 
documentations and raising efficiency by using 
electronic documentation systems. The associa-
tion also intends to continue promoting the use 
of cancer registry data for quality assurance in 
oncology, and for helping hospitals procure data 
for their quality reports.
The overall future development of cancer 
registration in Germany thus again looks posi-
tive. If the willingness of participating physicians 
and patients to report goes on increasing, and the 
financial and political support of the cancer regis-
tries continues, we will move one more step closer 
to the aim of achieving a population-based system 
of cancer registration covering the whole of Ger-
many that is informative and scientifically usable.
2    Methodological aspects
2 1  Completeness of cancer registration 
Since the benefit of population-based data on the 
incidence of cancer depends primarily on how 
completely all new cases of cancer are registered, 
the Federal Cancer Surveillance Unit ("Dachdo-
kumentation Krebs") at the Robert Koch Institute 
(RKI) regularly reviews the completeness and reli-
ability of the population-based cancer registries in 
Germany – currently in 13 states and two adminis-
trative districts. 
The following have proved to be reliable indi-
cators of the completeness of population-based 
cancer registries: 
(a) the DCO (death certificate only) percentage, 
(b)  the percentage of diagnoses that are microscop-
ically confirmed by examinations of tissue or 
cell/blood smears, and 
(c)  the ratio of mortality to incidence. DCO cases 
are cancer cases that only become known to the 
cancer registries via death certificates. 
Calculating the DCO percentage is a simple and 
reliable way of determining how completely data 
on cases are reported to – or collected by – a can-
cer registry. It is done by the regular, case-by-case 
matching of registry records on cancer patients 
against the records of the people who have died 
in the region. People who have died of cancer, but 
were not covered by the registry, and where no fur-
ther information on the disease is available, are 
added as DCO cases to the incidence figures. The 
'younger' a cancer registry is, the more likely it is German Registry of Cancer in Children, covers all of Germany (1980)
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The degree of completeness of cancer report-
ing to the registries in Germany estimated in 
this way has further increased compared to the 
5th edition of this brochure published in 2006 
(RKI's estimate of incidence from 1980 to 2002). 
Between 2002 and 2004 more than 95% of all 
cancer cases among women were registered at 
least once in four federal states, and more than 
95% of all cancer cases among men in five federal 
states. The degree of completeness of reporting 
to the population-based cancer registries in Ger-
many is particularly high in the case of cancers of 
the upper respiratory and digestive tracts (oral cav-
ity, pharynx, larynx, oesophagus) and breast can-
cer among women. Two thirds of German cancer 
registries covered more than 95% of these cancer 
cases at least once between 2002 and 2004. With 
two exceptions, all the population-based cancer 
registries in the 13 states with comprehensive can-
cer registration and two administrative districts 
registered more than 90% of all breast-cancer 
cases among the women in the respective catch-
ment area. 
Despite the progress that has been made in 
cancer registration in Germany, there are still defi-
cits in data acquisition. Reporting of cancers of the 
stomach, intestines, cervix, ovaries, kidney, blad-
der and thyroid gland is not yet complete enough. 
On the other hand, the registration figures for 
leukaemias and lymphomas have improved. The 
more cancer cases are covered in full by the pop-
ulation-based cancer registries in Germany, the 
more the exclusive dependence on data from the 
Saarland in parts of the RKI estimate (for example 
in the case of stomach cancer) can be reduced and 
the more reliable the results of the estimate will be 
for Germany as a whole. 
that DCO cases could be a result of people dying 
who were diagnosed with cancer before the reg-
istry was created and who, therefore, could not 
be covered by the registry. Therefore, a high DCO 
percentage among case reports in a cancer regis-
try that has not existed for long does not neces-
sarily mean that the current incidence figures are 
incomplete. Older gaps in cancer registration can 
also increase the current DCO percentage, which 
would understate the completeness of cancer 
registration. For this reason, the RKI's Federal 
Cancer Surveillance Unit also uses an additional 
method for assessing the completeness of cancer 
registration. 
The procedure is based on the completeness 
indicator that is generally used internationally: 
the mortality/incidence ratio. The incidence in a 
cancer registry's catchment area is estimated on 
the basis of data from a cancer registry in which 
registration is known to be complete. This "ref-
erence registry" is initially the Saarland Cancer 
Registry, the only population-based cancer regis-
try in Germany that has been working continu-
ously for over 40 years. On the assumption that 
diagnostics and therapies – and hence the sur-
vival – of cancer patients do not vary essentially 
from one federal state to another, and that dif-
ferent cancer risks can be reflected in the offi-
cial cause-of-death statistics, cancer incidence in 
the respective region can be estimated indirectly 
using the incidence and mortality quotients of 
the reference registry and the regional mortal-
ity figures. The development of the age-specific 
quotients over time is modelled in a log-linear 
approach with polynomial trends. Further reg-
istries are successively contributing to the data 
base of the reference registry, once the complete-
ness of these registries has been confirmed in a 
comparison with the Saarland. The resulting vir-
tual reference registry is ultimately composed of 
the records of all cancer registries in Germany in 
which registration is complete. Unlike the cus-
tomary completeness indicators – e.g. the DCO 
percentage and the percentage of microscopically 
confirmed diagnoses – the RKI estimate makes 
it possible to directly express the completeness 
of cancer registration. The percentage indicates 
the degree of completeness of the regional pop-
ulation-based cancer registries compared to the 
virtual reference registry. 
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2 2   Estimate and results for Germany in 2004
The Federal Cancer Surveillance Unit at the Robert 
Koch Institute (RKI) estimates the total number of 
new cancer cases per year in Germany on the basis 
of the data from the German population-based 
cancer registries in which registration is com-
plete. The current estimate covers a total period 
of 25 years between 1980 and 2004. The estimate 
for the years prior to 1990 is based exclusively on 
the Saarland Cancer Registry's data on incidence. 
Only thereafter is the basis of the estimate sup-
plemented by data from the other population-
based cancer registries in Germany that were set 
up later. However, the number of registries whose 
incidence data are fed into the estimate's data base 
varies according to cancer type. Whereas almost 
all the German cancer registries contribute data 
to the estimate on breast cancer in women, the 
estimate on stomach cancer in men relies exclu-
sively on data from the Saarland Cancer Registry 
(see section 2.1). 
The Robert Koch Institute's current estimate 
indicates a total of 436,500 new cases of can-
cer in Germany in 2004 (230,500 among men, 
206,000 among women, see table 2.2.1). In the 
same year cancer caused 208,824 deaths (110,745 
men, 98,079 women, see table 2.2.2). Figure 2.2.1 
shows the various cancer sites as a percentage 
of all new cases among men and women. A cor-
responding breakdown of cancer-related deaths 
is shown in Figure 2.2.2. The individual figures 
correspond to between 92 and 95% of all cancer 
cases and to 80 – 82% of all cancer-related deaths. 
The most common cancer among men is pros-
tate cancer, which accounts for 25% of all cases. 
In women, breast cancer accounts for as many as 
28% of all cases. 
About 10,000 of the total increase (approx. 
12,000) in the number of new cancer cases among 
men were cases of prostate cancer. Following an 
estimated 48,700 cases of prostate cancer in 2002, 
the current estimate is approximately 58,500 cases 
for 2004. The significantly higher prostate can-
cer figures can be explained to some extent by the 
trend in incidence rates in the current 1980 – 2004 
estimate. According to this, the number of cases 
rose by 4,500 between 2002 and 2004 alone. This 
development was probably primarily due to the 
increased use of PSA (prostate-specific antigen) 
in preliminary screening examinations for pros-
tate carcinoma. Only PSA screening has made the 
early detection of prostate cancer possible on this 
scale. 
The increase in prostate cancer figures can, 
however, also be attributed to the broadened data 
base used in the current estimate. For the first time, 
the completeness of cancer reporting exceeded 
95% for at least three consecutive years in another 
German population-based cancer registry apart 
from the Saarland Cancer Registry. This met the 
conditions for inclusion in the data pool of the cur-
rent estimate and led to a shift in the ratio between 
incidence and mortality in the case of prostate 
cancer. Although the number of deaths caused by 
prostate cancer is falling or remains unchanged, 
the number of cases diagnosed is still rising – for 
the reasons stated above, among others. 
Rising incidence figures for colorectal can-
cer (an increase of approx. 1,700 cases among 
men and of 200 among women compared to 
2002) and malignant melanoma of the skin (an 
increase of approx. 500 cases among men and of 
700 among women) should be seen in the context 
of more extensive screening. The screening strat-
egies for both cancer sites have been improved 
and are currently being optimized. Unlike malig-
nant melanoma of the skin, which is fully covered 
in many regional registries, up to now the RKI 
estimate on colorectal cancer has been essentially 
based on data from the Saarland Cancer Registry. 
Despite an unchanged overall number of new 
cancer cases among women, the current estimate 
on individual sites reveals more cases of breast, 
thyroid and lung cancer in women. In terms 
of absolute figures, the increase was highest in 
the case of breast cancer at around 2,000 cases, 
although the rise between 2002 and 2004 was 
less steep than in the previous years' estimates. 
The increase in thyroid cancer incidence among 
women in the same period (about 700 more cases 
in 2004) was higher than that of breast cancer. The 
larger number of thyroid cancer cases was prima-
rily the result of the first inclusion of incidence 
data from Bavaria in the national estimate. 2004 
also saw an increase in lung cancer among women 
(approx. 800 more cases), continuing the trend 
of the previous estimates. By contrast, incidence 
figures fell, for example, in the case of stomach 
cancer (by approx. 500 cases), ovarian and cervical 
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Site ICD-10 Men Women
Oral cavity and pharynx C00 – C14 7,620 2,780
Oesophagus C15 3,880 1,050
Stomach C16 11,000 7,780
Colon and rectum C18 – C21 37,250 36,000
Pancreas C25 6,320 6,620
Larynx C32 2,990 390
Lung C33, C34 32,850 13,190
Malignant melanoma of the skin C43 6,520 8,380
Breast in women C50 57,230
Cervix C53 6,190




Kidney and efferent urinary tract C64 – C66, C68 10,750 6,500
Bladder* C67, D09.0, D41.4 21,410 7,340
Thyroid gland C73 1,520 3,540
Hodgkin's disease C81 1,040 940
Non-Hodgkin lymphoma C82 – C85 6,780 6,070
Leukaemias C91 – C95 4,810 4,300
All malignant neoplasms, not 
incl. non-melanoma skin cancer C00 – C97 except C44 230,500 206,000
Table 2 2 1
Estimated number of new cancer cases in Germany in 2004
Source: RKI estimate for Germany in 2004
* including malignant neoplasms in situ and neoplasms of uncertain behaviour
Figure 2 2 1
Selected tumour sites as a percentage of all new cancer cases excluding non-melanoma skin cancer in Germany in 2004
Source: estimate by Federal Cancer Surveillance Unit at the Robert Koch Institute
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Site ICD-10 Men Women
Oral cavity and pharynx C00 – C14 3,450 994
Oesophagus C15 3,476 1,071
Stomach C16 6,276 5,197
Colon and rectum C18 – C21 13,748 14,034
Pancreas C25 6,412 6,596
Larynx C32 1,327 169
Lung C33, C34 28,820 11,026
Malignant melanoma of the skin C43 1,256 1,037
Breast in women C50 17,592
Cervix C53 1,660




Kidney and efferent urinary tract C64 – C66, C68 4,140 1,987
Bladder C67 3,565 2,629
Thyroid gland C73 231 445
Hodgkin's disease C81 201 158
Non-Hodgkin lymphoma C82 – C85 2,658 2,697
Leukaemias C91 – C95 3,738 3,327
All malignant neoplasms, not 
incl. non-melanoma skin cancer C00 – C97 except C44 110,745 98,079
Table 2 2 2
Number of cancer-related deaths in Germany in 2004
Source: official cause-of-death statistics, Federal Statistical Office, Wiesbaden
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Figure 2 2 2
Selected tumour sites as a percentage of all cancer-related deaths in Germany in 2004
Source: official cause-of-death statistics, Federal Statistical Office, Wiesbaden
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cancer (by 300 cases respectively) and leukaemias 
(by approx. 500 cases). 
Conclusion: a comparison of the 2002 inci-
dence figures (RKI estimate 1980-2002) with those 
for 2004 in the current estimate (1980-2004) shows 
that there has been no change in the total number 
of new cancer cases in women, despite the higher 
figures for the individual sites described above. 
This was caused by the markedly slower rise in the 
incidence figures for breast cancer in women. By 
contrast, there were bigger changes among men. 
According to the current RKI estimate, there were 
approx. 12,000 more new cases of cancer among 
men in 2004 than were recorded in the old esti-
mate for 2002. One cause can be found in the 
change in the population's age structure, espe-
cially among men. This higher estimate of current 
cancer cases is primarily a result of the increase 
of approximately 10,000 in prostate cancer cases, 
which was most likely caused by the increased use 
of blood PSA tests as a preliminary examination in 
prostate cancer screening. The RKI's current esti-
mate reflects this dynamic development in prostate 
cancer, because the number of population-based 
cancer registries in Germany in which registration 
is complete has increased, thus broadening the 
data base of the RKI estimate. 
Further improvements are to be expected, so 
that each new RKI estimate will be more reliable 
and representative than its predecessors.
2 3 Indicators and presentation
This section explains frequently used terms and 
provides further methodological information.
Incidence
Annual cancer incidence is defined as the total 
number of primary cases of cancer that occur in 
a defined population in the course of a year. A 
primary cancer originates in an organ or tissue 
and is neither an extension, nor a recurrence, nor 
a metastasis of a pre-existing cancer. The figure 
comprises all cancer cases, including second or 
third primary cancers affecting the same person. 
The incidence rate is calculated as an annual fig-
ure relative to population size. It is usually stated 
as a number per 100,000 residents per year. 
DCO percentage
Cancer cases which are not reported to a popu-
lation-based cancer registry during the patients' 
lifetimes and only find their way into statistics via 
a death certificate are referred to as DCO (death 
certificate only) cases; the data on these cases are 
added to the cancer figures of the year of death. 
The DCO percentage is a useful completeness 
indicator for established cancer registries. How-
ever, in recently established cancer registries the 
degree of completeness of data as calculated using 
the DCO percentage is understated. The DCO per-
centage can be expected to be higher in 'young' 
cancer registries, since it is possible that some 
of the people who have died of cancer were diag-
nosed before the registry was established, so that 
they could not be registered. The Federal Cancer 
Surveillance Unit, therefore, also assesses the 
completeness of cancer reporting in a different 
way (see section 2.1). 
Mortality
Cancer mortality is based on the number of can-
cer-related deaths in a year according to the official 
cause-of-death statistics. The deaths are assigned 
to the underlying cause of death according to age 
and gender. The mortality rate is the number of 
deaths relative to the size of the population. The 
rates are usually expressed per 100,000 people. 
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ICD 
The ICD (International Classification of Dis-
eases), which is occasionally revised, is used for 
coding diseases and causes of death. The 9th and 
10th revisions of the ICD were used in the period 
from 1980 to 2004. Whereas recently established 
cancer registries in Germany were able to use the 
10th revision for coding cancer sites from the out-
set, there was some delay in implementing it in 
the German cause-of-death statistics. In most of 
the cancer sites dealt with here, the continuity of 
mortality trends was hardly affected by the intro-
duction (in 1998) of the 10th revision of the ICD 
for coding the German cause-of-death statistics. 
Compared to coding according to the 9th revi-
sion (ICD-9: 140 – 208), ICD-10 led to 0.1%-0.3% 
higher death figures for all cancer sites (ICD-10: 
C00 – C97) and up to 2% lower death figures for 
ovarian cancer and non-Hodgkin lymphomas. 
Otherwise, the deviations were minimal. The 10th 
revision of the ICD was used in the present bro-
chure to designate cancer sites. 
Crude rates
A crude rate (of incidence or mortality) for a certain 
cancer site and population is calculated by dividing 
the total number of all new cancer cases in a given 
period (incidence), or the total number of deaths 
caused by a certain form of a cancer (mortality), by 
the total number of people making up the respec-
tive population (in this case the resident population 
of Germany). The result is usually given as a rate 
per 100,000 residents per year. 
Age-specific rates
The age-specific rate is determined by dividing the 
number of cancer cases and/or deaths in a certain 
age group by the corresponding number of men 
or women in this age group in the population. The 
age-specific incidence and mortality rates are usu-
ally given as annual rates per 100,000 resident 
members of the respective age group. 
Age-standardized rates 
Descriptive epidemiology compares the frequency 
(incidence or mortality) of a certain cancer site 
either in different populations or within the same 
region during different time periods. As shown 
by the information provided in this brochure on 
the age-specific incidence of cancer in men and 
women, the incidence rate usually increases con-
siderably with age. If, therefore, incidence or mor-
tality is to be compared in different states and 
regions, or within the same population at different 
times, the possibility that these differences might 
be caused exclusively by different age structures 
of the populations being compared must first be 
excluded by means of age standardization. As a 
rule, age standardization is carried out by weight-
ing the age-specific rates and subsequently add-
ing them together. Since the sum of the weights 
used is 1, the age-standardized rate can be regarded 
as a weighted average of age-specific rates. It indi-
cates how frequently a disease is contracted, or 
causes death, in a population of 100,000 people 
of a defined age structure. The European Stand-
ard and the World Standard are commonly used as 
standard populations in cancer epidemiology. The 
European Standard includes a higher percentage 
of older people than the World Standard – in line 
with higher life expectancy in Europe. In this bro-
chure, the World Standard is only used for inter-
national comparisons. In all other cases, the Euro-
pean Standard (old European standard population) 
is used for age standardization. 
Globocan 2002
Age-standardized incidence rates from neighbour-
ing European countries, North America, Australia 
and Japan from the Globocan 2002 software pack-
age are used to classify the level of estimated can-
cer incidence in Germany by international com-
parison. The cancer incidence rates, which were 
age-standardized according to the World Stand-
ard, relate to 2002. For comparison, two incidence 
rates in Germany that have been standardized in 
the same way are shown for 2002 (from the last 
1980 – 2002 estimate) and for 2004 (from the cur-
rent 1980 – crdc-2004 estimate). Age standardiza-
tion using the World Standard leads to lower inci-
dence rates than when the European Standard is 
used because it is based on a smaller proportion 
of older people. 
Average age at onset, average age of death
The average age at the onset of cancer and the aver-
age age of death are determined as a median of 
the age distribution of all cancer patients and all 
deceased respectively. The figures are therefore less 
influenced by the extremes of this distribution – i.e. 
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a five-year observation period. This new approach 
makes it possible to calculate more recent 5-year 
survival rates.
The survival prospects of individual cancer 
patients depend not only on the cancer site, but 
also on the stage of the disease when diagnosed 
and the age of the patient. An individual progno-
sis cannot be drawn up on the basis of these data. 
They can only serve as an orientation for patients, 
family members and the interested public. 
Graphic presentation
The age-specific incidence rates show the relation 
between age and cancer risk and enable a compari-
son of cancer incidence in the two sexes. 
Only the relation between the rates should 
be taken into account when making an interna-
tional comparison between the age-standardized 
incidence rates of different countries with the end 
points of the RKI's previous estimate (1980 – 2002) 
and current estimate (1980 – 2004). The absolute 
level of the incidence rates turns out lower when 
the World Standard for age standardization is 
applied rather than the European Standard, which 
is used otherwise. 
The trend in age-standardized cancer mor-
tality rates during the period 1980-2004 is based 
on data from the official cause-of-death statistics, 
which were calculated retrospectively for a united 
Germany as far back as 1980. The figures on new 
cancer cases in Germany estimated by the RKI are 
presented as age-standardized rates for the same 
period from 1980 up to and including 2004. 
The currently (2003 – 2004) measured age-
standardized incidence rates (European stand-
ard population) in 13 German states and the two 
administrative districts (Münster for North Rhine-
Westphalia and Darmstadt for Hesse) are shown 
in comparison to the RKI estimate for Germany 
(2003 – 2004). Regional incidence rates for the 
administrative district of Darmstadt in Hesse are 
shown for the first time. The only state where 
population-based data on cancer cases are still not 
available is Baden-Württemberg, whose cancer 
registry is under development (see section 1.3). 
The completeness of cancer registration by 
the population-based cancer registries is shown 
by different colours in the charts and tables. Reg-
istration of at least 90% of cancer cases between 
2003 and 2004 is indicated by a darker colour on 
the youngest and oldest – than if the arithmetic 
mean were chosen. The median age divides the 
patients and deceased into two equal halves, one 
younger and one older, each of the same size. 
Relative survival rates
Population-based relative survival rates are calcu-
lated to assess survival after a cancer is diagnosed. 
To do this, the patients' survival period is related 
to the life expectancy of the general population. A 
relative survival rate of 100% means that the mor-
tality of the cancer patients is just as high as that of 
the general population of the same age. 
Although data on cancer survival are availa-
ble in various population-based cancer registries 
in the meantime, this edition of "Cancer in Ger-
many" is again focusing on data from the Saar-
land Cancer Registry to calculate the survival rates. 
This is because the methodological comparability 
of the cancer survival data between the registries 
is currently not yet sufficiently assured. Only the 
date of diagnosis and (in the event of the patient's 
death) the date of death were used for the calcula-
tion, irrespective of the certified causes of death. 
The registry collects information on the date of 
death by means of the annual "mortality match" – 
by comparing the data on all the people who have 
died in the Saarland in the respective year with 
the registry's data. The calculations cover the sur-
vival of more than 95% of all cancer patients in the 
Saarland. Only DCO cases with no date of diagno-
sis, and cancer patients who were diagnosed by 
autopsy only, had to be excluded. 
Unlike earlier editions of this brochure, the 
calculation of survival excludes people under the 
age of 15, since the German Childhood Cancer Reg-
istry in Mainz already calculates the survival rates 
of all children and young people with cancer in 
Germany (see section 4). By restricting the calcula-
tion to cancer patients over 15, the relative survival 
rates – of leukaemia patients, for example – could 
turn out worse than the figures published in the 
5th edition of this brochure. Another change is 
that we used national life tables instead of the Saar-
land tables for the years 1999 to 2005 and based 
our calculations on the period approach instead of 
the traditional cohort approach. The survival rates 
now relate to diagnosis and survival in the more 
recent period from 2000 to 2004 as opposed to 
1994 – 1998 as the years of diagnosis followed by 
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the incidence bars. The incidence bar is lighter in 
colour if the completeness of coverage is below 
90%. The DCO percentage of age-standardized 
and crude incidence, which is shown in the charts 
and tables, is also a good indicator of complete-
ness. In the chart, the DCO percentage at the end 
of each bar is shown in a lighter colour to distin-
guish it from the completely or less completely 
registered reports on incident cancer cases. In the 
alphabetically listed table following the bar charts, 
the crude and age-standardized incidence rates 
based on sufficiently complete data between 2003 
and 2004 are shown in black characters; otherwise 
they are grey. The DCO percentage in the table 
relates to the crude incidence rate. 
3    Results according to ICD-10
3 1  All cancer sites
Prevalence
The category 'all cancer sites' is defined as all 
malignant neoplasms, including primary systemic 
lymphomas and leukaemias. In line with interna-
tional practice, non-melanoma skin cancer is not 
included. The annual number of new cases of can-
cer in Germany is estimated at approx. 230,500 
among men and 206,000 among women. The 
average age at onset is about 69 in both men and 
women. The average age of death from cancer is 
about 71 for men and 75 for women. Compared 
to the last estimate for 2002, this represents an 
increase in the incidence rate among men of just 
over 5%, essentially due to a higher incidence of 
prostate cancer. The total number of new cases 
among women has not changed since the last esti-
mate.
Risk factors
As a rule, cancer develops as a result of not one 
single cause but a combination of many different 
factors. On the basis of present knowledge, preven-
tion or early detection is only feasible in a few of the 
more common types of tumour. The vaccination of 
12-to 17-year-old girls against the human papilloma-
virus (HPV), which was approved for the first time 
in 2007, is currently of major importance. In the 
long term, it is hoped that this will reduce the inci-
dence of cervical cancer. Of the avoidable risk fac-
tors, (cigarette) smoking is of outstanding signifi-
cance since it causes between a quarter and a third 
of all cancer-related deaths. A less precisely quan-
tifiable, but perhaps even higher percentage of all 
cancer-related deaths can probably be attributed to 
poor diet, such as general supernutrition and con-
suming too much (animal) fat and not enough fruit 
and vegetables. Further risk factors contributing to 
the development of certain cancers include chronic 
infections, heavy alcohol consumption, exposure to 
carcinogens at the workplace, and environmental 
effects. Workplace and environmental influences 
include the ultraviolet components of sunlight, 
fine particulate matter, polycyclic aromatic hydro-
4 1  All cancer sites but skin
18 Cancer in Germany     All cancer sites
Survival
The relative 5-year cancer survival rates cover a 
broad range – from very favourable rates for lip can-
cer, malignant melanoma of the skin and testicular 
cancer, to very unfavourable rates for pancreatic, 
lung and oesophageal cancer. The survival rates of 
cancer patients have been improving overall since 
the 1970s. The lower incidence of stomach cancer, 
which has a poor survival rate, and the higher inci-
dence of colorectal cancer with a better rate, have 
also contributed to this improvement. Comparing 
the 4th edition of this brochure (2004) – with the 
survival rates of patients diagnosed between 1990 
and 1994 – with the 5th edition (2006) – with sur-
vival rates for the period 1994 – 1998 – the rela-
tive survival rates for all cancer sites improved by 
two percentage points in each case. Recent survival 
data for the years 2000 to 2004, now examined 
by means of period analysis, reveal relative 5-year 
survival rates of 60% for women and 53% for men. 
In the case of men, this means an improvement of 
five percentage points, in women of seven. 
The more marked improvement in the sur-
vival prospects of men was essentially due to the 
considerable rise in the number of new cases of 
prostate cancer, which is now being detected ear-
lier, thanks to PSA screening becoming more com-
mon. It should be noted here that an earlier diag-
nosis does not necessarily prolong life.
The markedly higher survival rates of women 
with cancer can be attributed to differences in 
cancer patterns. Lung and oesophageal cancer 
(with poor chances of survival) are more com-
mon among men, while breast cancer (which has 
a favourable prognosis) occurs much more fre-
quently among women. There is little difference 
between women and men when it comes to the 
average survival prospects of patients with cancers 
of the same site.
carbons (PAHs) (e.g. from car exhausts and indus-
trial emissions), radon and passive smoking inside 
buildings. The effects of these harmful substances 
combine in a wide variety of ways in the course of 
a person's lifetime, so that it is rarely possible to 
confirm a suspected cause in individual cases.
Trends
In the Saarland, the age-standardized incidence 
rate rose during the 1970s and 1980s among both 
men (whose rate of new cancer cases was higher) 
and women (whose rate was lower). 
Since 1980 the estimated incidence rates for 
Germany have indicated similar, rising trends for 
the two sexes, albeit at different levels. The rise in 
incidence among men since the 1990s was most 
likely caused by prostate cancer (see C61: prostate 
carcinoma) being diagnosed more often and at a 
younger age. A comparison of consecutive RKI 
estimates shows that there was a rise in overall 
cancer incidence among men in the 60 – 79 age 
group, and a decline among men over 80 (earlier 
diagnosis). 
A comparison of the estimates for 2002 and 
2004 among women shows no rise in cancer 
incidence in specific age groups, only a decrease 
among women over 80.
The age-standardized cancer mortality rate 
has been falling continuously among women since 
1970, and among men since the mid-1980s.
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Figure 3 1 1
Estimated age-specific incidence in Germany in 2004, ICD-10 C00 –97 except C44
New cases per 100,000 by age groups
Figure 3 1 2
Age-standardized incidence rates in Germany in 2002 according to the RKI's 1980 – 2002 estimates,  
and in 2004 according to the RKI's 1980 – 2004 estimates, compared internationally, ICD-10 C00 – 97 except C44
Incidence per 100,000 (World Standard)
Source: Globocan estimate 2002, the RKI's 2002 and 2004 estimates for Germany
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Age in years Men Women
Incidence Mortality Incidence Mortality
under 15 11.5 2.6 8.6 2.2
15 to under 35 42.7 6.1 49.1 6.2
35 to under 40 75.8 17.5 127.1 22.5
40 to under 45 121.8 40.2 222.7 45.9
45 to under 50 228.0 92.5 330.6 91.8
50 to under 55 421.4 188.7 524.7 148.3
55 to under 60 794.5 326.6 708.2 232.5
60 to under 65 1,315.2 532.3 871.2 317.1
65 to under 70 1,899.6 784.3 1,045.3 434.5
70 to under 75 2,567.9 1,162.9 1,224.1 619.6
75 to under 80 2,909.0 1,611.9 1,518.2 871.7
80 to under 85 2,912.8 2,156.9 1,738.9 1,186.7
85 and older 2,607.8 2,622.7 1,852.0 1,616.1
Crude rate 571.2 274.1 488.7 232.4
Stand. rate (European standard) 453.6 218.5 330.8 135.0
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Table 3 1 1
Incidence and mortality by age group in Germany in 2004, ICD-10 C00 – 97 except C44
Cases/deaths per 100,000 by age groups
Figure 3 1 3
Age-standardized incidence and mortality in Germany, 1980 – 2004, ICD-10 C00 – 97 except C44
Cases/deaths per 100,000 (European Standard)
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Region Men Women
Crude rate % DCO Stand  rate* Crude rate % DCO Stand  rate*
Baden-Württemberg registry currently being developed
Bavaria 535.6 20 445.1 465.3 22 322.8
Berlin 420.4 26 374.0 420.9 28 287.5
Brandenburg 590.3 12 481.9 472.4 15 312.3
Bremen 662.0 9 504.5 571.4 7 363.4
Hamburg 491.9 8 410.8 448.6 8 309.2
Hesse (Darmstadt admin. dist.) 460.2 45 370.0 384.0 45 252.1
Mecklenburg-Western Pomerania 562.3 11 470.6 448.0 11 299.7
Lower Saxony 666.2 20 529.5 561.8 23 371.3
North Rhine-Westphalia (Münster admin. dist.) 532.9 10 449.3 440.9 10 308.2
Rhineland-Palatinate 568.2 22 445.1 496.5 24 325.0
Saarland 661.2 4 497.4 534.0 5 346.4
Saxony 593.6 15 443.5 501.2 15 296.2
Saxony-Anhalt 555.3 23 426.4 449.7 23 275.4
Schleswig-Holstein 657.1 16 510.0 572.5 19 386.3
Thuringia 551.5 19 438.8 468.6 18 295.2
Germany, estimated 563 1 4 452 7 485 9 5 330 2
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Registered incidence in the regions of Germany, 2003 – 2004, ICD-10 C00 – 97 except C44
New cases per 100,000 (*European Standard)
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Trends
The incidence of cancers of the mouth and phar-
ynx increased considerably among men up to the 
early 1990s in Germany. Since then the trend has 
been falling just as markedly. Among women, inci-
dence rose up to the late 1990s; since then it has 
been steady, recently moving towards a decline. 
Mortality due to these tumours shows a similar 
curve shape with lower rates respectively. Among 
men, mortality first rose and then fell in the early 
1990s, whereas among women this decline began 
in the late 1990s. 
Survival
The relative 5-year survival rates for all sites of the 
oral cavity and the pharynx are 47% in men and 
55% in women. Factors affecting women which 
contribute to this difference include a more favour-
able composition of this group of cancers and the 
stages at which they are diagnosed. 
Of this group, cancer of the lip has the most 
favourable 5-year survival rates at over 90%; can-
cer of the pharynx has the most unfavourable at 
30 – 40%.
Prevalence
Cancers of the oral cavity and the pharynx include 
malignant neoplasms of the lip, the tongue, the 
floor and roof of the mouth, the salivary glands 
and the pharynx. Men are diagnosed with cancer 
of the oral cavity and pharynx much more fre-
quently than women. In Germany, the estimated 
annual number of new cases among men (7,600) 
is almost three times as high as among women 
(2,800). These cancer sites account for 3.3% of 
all new cancer cases among men and are the sev-
enth most common in terms of incidence (among 
women: 1.4%, 15th). Annual deaths caused by can-
cer of the oral cavity and the pharynx total 3,450 
among men, which corresponds to 3.1% of all can-
cer-related deaths (women: 994, 1.0%). The aver-
age age at onset of the disease is low compared 
to other cancer sites; it is 61 among men and 
63 among women. The highest incidence rates 
among men are in the 55 – 65 age group.
Risk factors
The main risk factors include tobacco and alcohol 
consumption. Smokers develop malignant neo-
plasms of the oral cavity and the pharynx up to six 
times more frequently than non-smokers, and the 
combination of alcohol consumption and smoking 
increases the risk. Oral tobacco use (e.g. chewing 
tobacco) also represents a risk. Other risk factors 
are poor oral hygiene and insufficient consump-
tion of fruit and vegetables. Viruses are also under 
discussion as contributory factors to the develop-
ment of some subtypes of these cancers.
3 2  Oral cavity and pharynx
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Figure 3 2 1
Estimated age-specific incidence in Germany in 2004, ICD-10 C00 –14
New cases per 100,000 by age groups
Figure 3 2 2
Age-standardized incidence rates in Germany in 2002 according to the RKI's 1980 – 2002 estimates,  
and in 2004 according to the RKI's 1980 – 2004 estimates, compared internationally, ICD-10 C00 –14
Incidence per 100,000 (World Standard)
Source: Globocan estimate 2002, the RKI's 2002 and 2004 estimates for Germany
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Incidence Mortality Incidence  Mortality 
Men        Women
Age in years Men Women
Incidence Mortality Incidence Mortality
under 15 0.0 0.0 0.0 0.0
15 to under 35 0.5 0.1 0.5 0.0
35 to under 40 1.7 0.9 1.6 0.3
40 to under 45 8.6 2.9 2.8 0.7
45 to under 50 27.4 9.6 7.2 1.9
50 to under 55 43.5 16.7 11.8 3.1
55 to under 60 53.7 21.0 16.8 5.2
60 to under 65 51.4 25.7 15.7 5.2
65 to under 70 47.7 23.4 13.2 4.5
70 to under 75 45.4 22.6 14.1 4.2
75 to under 80 37.2 22.6 12.5 4.8
80 to under 85 31.1 20.9 14.6 8.2
85 and older 32.0 25.4 16.6 13.9
Crude rate 18.9 8.5 6.6 2.4
Stand. rate (European standard) 16.3 7.2 5.1 1.6
Table 3 2 1
Incidence and mortality by age group in Germany in 2004, ICD-10 C00 –14
Cases/deaths per 100,000 by age groups
Figure 3 2 3
Age-standardized incidence and mortality in Germany, 1980 – 2004, ICD-10 C00 –14
Cases/deaths per 100,000 (European Standard)
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Registered incidence in the regions of Germany, 2003 – 2004, ICD-10 C00 – 14
New cases per 100,000 (*European Standard)
26
Trends
Oesophageal cancer incidence and mortality rates 
are almost identical due to the unfavourable prog-
nosis for oesophageal carcinomas. Incidence rates 
in men rose slightly up to the mid-1990s; estimated 
incidence shows a slightly decreasing trend over 
the last few years. Both the incidence and mortal-
ity rates among women increased slightly in the 
period up to 2004. 
Survival
For a long time the survival rates of patients with 
an oesophageal carcinoma were among the most 
unfavourable of all cancers. The relative 5-year sur-
vival rate is currently around 22% in men and 20% 
in women. This means that the overall prospects 
of survival after being diagnosed with oesophageal 
cancer have improved in recent years, especially 
for men.
Prevalence
Approx. 3,900 men and 1,050 women are diag-
nosed with oesophageal cancer each year in Ger-
many. This corresponds to 1.7% of all malignant 
neoplasms in men and 0.5% in women. Oesopha-
geal cancer is responsible for a higher percent-
age of cancer-related deaths: 3.1% among men and 
1.1% among women. Men in Germany currently 
develop oesophageal cancer about three times 
more frequently and on average 4.5 years earlier 
than women. At 65, the average age at onset in 
men is four years below the figure for all cancer 
sites; in women (almost 70) it is one year above the 
overall figure. Most of the common squamous-cell 
carcinomas of the oesophagus are located in the 
middle and lower third of the oesophagus, only 
ten to fifteen percent in the upper third. Aden-
ocarcinomas, which originate at the entrance to 
the stomach (cardia), are also located in the lower 
third.
Risk factors
Alcohol and tobacco consumption are among the 
most important risk factors in the development of 
squamous-cell carcinomas in the oesophagus, and 
a combination of both factors further aggravates 
the effect. Adenocarcinomas tend to develop from 
a reflux disease. Barrett's oesophagus and Barrett's 
ulcer, a lesion of the mucous membrane caused by 
frequent reflux with heartburn (due to the backing 
up of stomach contents into the oesophagus), are 
regarded as precancerous lesions. Diet-related risk 
factors and overweight, therefore, also play a role, 
at least indirectly. Familial clustering of oesopha-
geal cancer has been observed.
3 3  Oesophagus
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Figure 3 3 1
Estimated age-specific incidence in Germany in 2004, ICD-10 C15
New cases per 100,000 by age groups
Figure 3 3 2
Age-standardized incidence rates in Germany in 2002 according to the RKI's 1980 – 2002 estimates,  
and in 2004 according to the RKI's 1980 – 2004 estimates, compared internationally, ICD-10 C15
Incidence per 100,000 (World Standard)
Source: Globocan estimate 2002, the RKI's 2002 and 2004 estimates for Germany
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Incidence Mortality Incidence  Mortality 
Men        Women
Age in years Men Women
Incidence Mortality Incidence Mortality
under 15 0.0 0.0 0.0 0.0
15 to under 35 0.1 0.1 0.0 0.0
35 to under 40 0.8 0.6 0.0 0.0
40 to under 45 2.0 1.6 0.3 0.1
45 to under 50 6.7 4.7 1.3 1.1
50 to under 55 14.0 11.3 2.7 2.3
55 to under 60 21.7 19.1 5.0 3.8
60 to under 65 28.1 24.0 5.3 4.6
65 to under 70 34.8 29.0 5.7 5.6
70 to under 75 33.5 30.3 7.2 5.6
75 to under 80 29.5 32.4 7.5 8.8
80 to under 85 26.3 33.3 9.2 11.1
85 and older 23.2 33.7 9.3 16.2
Crude rate 9.6 8.6 2.5 2.5
Stand. rate (European standard) 7.9 7.0 1.7 1.6
Cancer in Germany     Oesophagus
Table 3 3 1
Incidence and mortality by age group in Germany in 2004, ICD-10 C15
Cases/deaths per 100,000 by age groups
Figure 3 3 3
Age-standardized incidence and mortality in Germany, 1980 – 2004, ICD-10 C15
Cases/deaths per 100,000 (European Standard)
29
 18 15 12 9 6 3 0 0 1 2 3 4 5 6
       Meckl.-Western Pom.                       
                Schleswig-Holstein              
 Brandenburg              
Lower Saxony             
Hamburg            
                                       Saarland           
Bremen          
  Saxony-Anhalt          
NRW (Münster dist.)         
   Saxony         
   Rhineland-Palatinate        
 Bavaria        
Berlin       
Hesse (Darmstadt dist.)      
                       Germany, estimated     
                      Thuringia
                         Bremen
                        Hamburg
                       Berlin
                      Schleswig-Holstein
                    Lower Saxony
                    Hesse (Darmstadt dist.)
                    NRW (Münster dist.)
                 Saarland
            Meckl.-Western Pom.
            Germany, estimated
           Brandenburg
           Rhineland-Palatinate
         Bavaria
     Saxony-Anhalt
    Saxony    
Thuringia
       Men     Women
cases DCO casesless than 90% registration rate: casesat least 90% registration: 
Region Men Women
Crude rate % DCO Stand  rate* Crude rate % DCO Stand  rate*
Baden-Württemberg registry currently being developed
Bavaria 10.0 18 8.6 2.1 34 1.4
Berlin 9.8 33 8.4 3.7 41 2.5
Brandenburg 12.0 11 9.7 2.7 25 1.6
Bremen 11.2 8 9.0 4.8 12 2.6
Hamburg 11.0 10 9.3 3.7 14 2.5
Hesse (Darmstadt admin. dist.) 10.1 56 8.2 3.4 57 2.2
Mecklenburg-Western Pomerania 14.9 7 12.0 2.6 11 1.7
Lower Saxony 11.8 15 9.6 3.4 23 2.2
North Rhine-Westphalia (Münster admin. dist.) 10.2 12 8.9 3.4 18 2.2
Rhineland-Palatinate 10.6 20 8.6 2.3 33 1.6
Saarland 12.1 5 9.1 3.3 0 2.0
Saxony 11.5 18 8.8 2.1 18 1.1
Saxony-Anhalt 11.5 27 9.0 2.1 38 1.1
Schleswig-Holstein 12.5 16 9.9 3.6 25 2.4
Thuringia 8.6 17 6.7 1.4 29 0.8
Germany, estimated 9 6 3 7 9 2 5 4 1 6
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Registered age-standardized incidence in the regions of Germany, 2003 – 2004, ICD-10 C15
New cases per 100,000 (European Standard)
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Registered incidence in the regions of Germany, 2003 – 2004, ICD-10 C15
New cases per 100,000 (*European Standard)
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Trends
As in other industrialized nations, the number of 
new stomach cancer cases in Germany has been 
falling continuously for over 30 years. The esti-
mated incidence in Germany in 2004 was mark-
edly lower than in 1980 among both men and 
women; among women the figure was halved. 
Mortality due to stomach cancer is also decreas-
ing continuously, especially in women.
Survival
Among both men and women, the cumulated rela-
tive 5-year survival rates for stomach cancer are 
still rather poor compared to other cancers; the 
figures are 35% and 31% respectively.
Prevalence
The number of incident cases in Germany is esti-
mated at approx. 18,800 per annum; almost 11,000 
of these are among men. Stomach cancer is the 
fifth most common cancer among men and the 
seventh among women. Despite falling incidence 
rates, stomach cancer is still a common tumour-
related cause of death. The average age at onset 
is approx. 70 in men and 75 in women; it is thus 
almost one year higher among men and six years 
higher among women than for all cancer sites. 
Histologically, adenocarcinomas are the most com-
mon carcinomas in the stomach. MALT lympho-
mas, which originate in the gastric mucosa (stom-
ach lining), are not classified as stomach cancer, 
but as non-Hodgkin lymphomas.
Risk factors
Eating habits play a major role. In particular a lack 
of fresh fruit and vegetables reduces risk, whereas 
the frequent consumption of highly salted meals 
increases risk. Consumption of grilled, pickled or 
smoked foods also seems to promote the develop-
ment of stomach cancer. Excessive consumption 
of alcohol also increases the risk of developing the 
disease, because this promotes long-term inflam-
mations involving lesions of the gastric mucosa, 
such as chronic atrophic gastritis (especially type 
B) and stomach ulcers. Smoking is also considered 
a risk factor. It has been shown in recent years 
that a bacterial infection of the stomach with Heli-
cobacter pylori is of major importance in the ini-
tiation and promotion of stomach cancer. Among 
stomach polyps, which are virtually always benign, 
only the rare adenomas are regarded as precancer-
ous. Pernicious anaemia, Ménétrier's disease and 
other rare pre-existing diseases only lead to a small 
proportionate increase in the risk. 
3 4  Stomach
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Figure 3 4 1
Estimated age-specific incidence in Germany in 2004, ICD-10 C16
New cases per 100,000 by age groups
Figure 3 4 2
Age-standardized incidence rates in Germany in 2002 according to the RKI's 1980 – 2002 estimates,  
and in 2004 according to the RKI's 1980 – 2004 estimates, compared internationally, ICD-10 C16
Incidence per 100,000 (World Standard)
Source: Globocan estimate 2002, the RKI's 2002 and 2004 estimates for Germany
ICD-10 C16     Cancer in Germany
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Men        Women
Age in years Men Women
Incidence Mortality Incidence Mortality
under 15 0.0 0.0 0.0 0.0
15 to under 35 0.4 0.2 0.2 0.3
35 to under 40 2.2 1.0 1.9 1.4
40 to under 45 8.8 3.2 4.1 2.3
45 to under 50 16.4 5.3 5.7 4.0
50 to under 55 16.8 11.3 14.1 6.2
55 to under 60 38.5 16.6 14.4 8.5
60 to under 65 52.2 26.4 24.3 12.4
65 to under 70 73.4 39.7 29.6 17.5
70 to under 75 116.3 67.0 64.3 29.8
75 to under 80 155.4 96.4 72.6 46.1
80 to under 85 189.2 133.4 92.9 68.7
85 and older 222.9 175.4 119.5 124.1
Crude rate 27.3 15.6 18.5 12.3
Stand. rate (European standard) 21.8 12.4 10.6 6.6
Cancer in Germany     Stomach
Table 3 4 1
Incidence and mortality by age group in Germany in 2004, ICD-10 C16
Cases/deaths per 100,000 by age groups
Figure 3 4 3
Age-standardized incidence and mortality in Germany, 1980 – 2004, ICD-10 C16
Cases/deaths per 100,000 (European Standard)
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cases DCO casesless than 90% registration rate: casesat least 90% registration: 
Region Men Women
Crude rate % DCO Stand  rate* Crude rate % DCO Stand  rate*
Baden-Württemberg registry currently being developed
Bavaria 23.8 26 19.5 18.8 31 10.9
Berlin 16.7 32 15.1 14.2 42 8.2
Brandenburg 27.0 17 23.2 18.9 25 10.9
Bremen 20.0 7 15.2 17.2 5 9.1
Hamburg 16.7 11 13.8 14.1 14 8.3
Hesse (Darmstadt admin. dist.) 18.1 53 14.4 14.1 55 7.9
Mecklenburg-Western Pomerania 26.9 17 23.3 21.5 19 12.7
Lower Saxony 26.0 16 20.5 19.0 21 10.7
North Rhine-Westphalia (Münster admin. dist.) 20.8 12 18.1 16.0 14 9.4
Rhineland-Palatinate 21.3 26 17.0 16.7 33 9.4
Saarland 25.1 1 19.3 18.3 9 9.4
Saxony 30.0 21 22.5 24.0 27 11.7
Saxony-Anhalt 27.5 33 21.3 19.2 39 10.6
Schleswig-Holstein 25.4 15 19.5 19.3 21 11.0
Thuringia 26.8 28 21.8 20.2 36 10.8
Germany, estimated 27 3 3 22 1 18 8 6 10 9
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Registered age-standardized incidence in the regions of Germany, 2003 – 2004, ICD-10 C16
New cases per 100,000 (European Standard)
Table 3 4 2
Registered incidence in the regions of Germany, 2003 – 2004, ICD-10 C16
New cases per 100,000 (*European Standard)
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repeat examination after ten years. Alternatively, 
insured people who do not participate in colonos-
copy screening can have a regular haemoccult test 
every two years from the age of 55. At present it is 
still too early to judge the influence of the newly 
regulated colorectal cancer screening by colonos-
copy on the incidence of colorectal cancer.
Trends
The estimated incidence rates in both men and 
women have remained almost unchanged (at dif-
ferent levels) over the last ten years, following an 
upward trend during the 1980s. Unlike the inci-
dence trend, the mortality rates from colorectal 
cancer are falling continuously for both sexes. 
Survival
The cumulated, relative 5-year survival rates for 
colorectal cancer are about 60% among both men 
and women in the meantime.
Prevalence
Colorectal cancer is used here as a collective term 
to cover cancers of the colon, the rectum and the 
anus. Virtually all colorectal carcinomas are aden-
ocarcinomas, except anal carcinomas, which are 
predominantly squamous-cell carcinomas. How-
ever, since anal carcinomas only make up a around 
one percent of colorectal tumours, the following 
statements also apply to colorectal carcinomas 
alone. 
Colorectal cancer is the second most common 
cancer site in both sexes. The annual number of 
new cases of cancer in Germany is estimated at 
over 37,000 among men and about 36,000 among 
women. The average age at diagnosis is 69 in men 
and 75 among women. Colorectal cancer is fur-
thermore the second most common cause of death 
due to cancer among both women and men.
Risk factors
Diet-related factors – especially a low-fibre, high-
fat diet, a high proportion of red (iron-containing) 
meat (e.g. beef or pork as opposed to poultry) and 
a small proportion of vegetables, as well as regular 
alcohol consumption – increase the risk of devel-
oping colorectal cancer, as do overweight and lack 
of exercise. First-degree relatives of patients with 
colorectal cancer are themselves affected more fre-
quently than the average; it has not yet been finally 
clarified whether this is due to genetic modifica-
tions or a similar life-style. In the case of familial 
adenomatous polyposis (FAP), a very rare inher-
ited disease, and hereditary non-polyposis colorec-
tal cancer syndrome (HNPCC), cases of colorectal 
cancer are more likely to occur in members of the 
affected families at a young age. To a lesser extent, 
chronic-inflammatory intestinal diseases, e.g. coli-
tis ulcerosa, also increase the cancer risk. 
Cancer-screening procedures for colorectal 
cancer have recently been changed. People aged 
between 50 and 54 who are covered by statutory 
health insurance are now offered an annual test for 
hidden blood in the faeces (haemoccult test) as part 
of nationwide cancer screening. Everyone aged 55 
or above is entitled to a colonoscopy, including a 
3 5  Colon and rectum
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Figure 3 5 1
Estimated age-specific incidence in Germany in 2004, ICD-10 C18 – 21
New cases per 100,000 by age groups
Figure 3 5 2
Age-standardized incidence rates in Germany in 2002 according to the RKI's 1980 – 2002 estimates,  
and in 2004 according to the RKI's 1980 – 2004 estimates, compared internationally, ICD-10 C18 – 21
Incidence per 100,000 (World Standard)
Source: Globocan estimate 2002, the RKI's 2002 and 2004 estimates for Germany
ICD-10 C18 – 21     Cancer in Germany
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Incidence Mortality Incidence  Mortality 
Men        Women
Age in years Men Women
Incidence Mortality Incidence Mortality
under 15 0.0 0.0 0.0 0.0
15 to under 35 1.5 0.4 1.9 0.4
35 to under 40 6.9 1.4 7.6 1.6
40 to under 45 15.5 3.7 13.3 2.4
45 to under 50 28.5 7.3 26.3 6.2
50 to under 55 60.1 17.7 54.8 12.0
55 to under 60 130.5 34.9 80.7 21.0
60 to under 65 215.5 62.4 122.7 30.9
65 to under 70 317.7 98.5 169.3 48.6
70 to under 75 427.7 150.4 246.2 82.3
75 to under 80 481.8 207.8 358.8 134.8
80 to under 85 539.1 310.9 460.9 214.4
85 and older 524.3 378.3 469.3 330.6
Crude rate 92.3 34.1 85.4 33.3
Stand. rate (European standard) 72.6 26.9 49.3 17.0
Cancer in Germany     Colon and rectum
Table 3 1 1
Incidence and mortality by age group in Germany in 2004, ICD-10 C18 – 21
Cases/deaths per 100,000 by age groups
Figure 3 5 3
Age-standardized incidence and mortality in Germany, 1980 – 2004, ICD-10 C18 – 21
Cases/deaths per 100,000 (European Standard)
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Bremen 90.6 4 67.6 95.1 5 50.3
Hamburg 60.0 7 49.0 62.0 10 35.1
Hesse (Darmstadt admin. dist.) 62.1 39 49.4 58.1 44 33.7
Mecklenburg-Western Pomerania 75.2 10 63.8 65.5 11 38.7
Lower Saxony 96.7 17 76.2 93.1 22 52.3
North Rhine-Westphalia (Münster admin. dist.) 78.4 6 65.2 73.1 10 43.6
Rhineland-Palatinate 89.5 14 69.0 82.7 21 46.2
Saarland 107.7 1 79.3 89.7 3 50.5
Saxony 87.4 10 64.3 75.3 13 38.6
Saxony-Anhalt 76.8 18 58.0 64.5 25 34.0
Schleswig-Holstein 89.0 11 67.6 85.6 14 49.1
Thuringia 83.5 17 65.6 70.7 20 39.6
Germany, estimated 91 3 2 72 7 85 3 3 49 6
                                                                                                      — at least 90% registration     —  less than 90% registration rate
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Figure 3 5 4
Registered age-standardized incidence in the regions of Germany, 2003 – 2004, ICD-10 C18 – 21
New cases per 100,000 (European Standard)
Table 3 5 2
Registered incidence in the regions of Germany, 2003 – 2004, ICD-10 C18 – 21
New cases per 100,000 (*European Standard)
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Trends
Both the estimated incidence rates and mortality 
due to pancreatic cancer have remained constant 
among men since the late 1980s in Germany. In 
women, both incidence and mortality are rising 
slightly.
Survival
Malignant neoplasm of the pancreas is a cancer 
site with rare and uncharacteristic early symptoms. 
Pancreatic carcinomas are therefore frequently not 
diagnosed until they are at an advanced stage. The 
chances of a cure are still very poor for the over-
whelming majority of patients. The relative 5-year 
survival rate for people with pancreatic cancer is 
decidedly unfavourable. It is about 6.4% in men 
and 7.6%. for women
Prevalence
In Germany, the annual number of new cases of 
pancreatic cancer is estimated at approx. 6,300 
among men and 6,600 among women. Pancreatic 
carcinomas account for about 3% of all cancers. 
However, they are responsible for 5.8% of all can-
cer-related deaths among men and 6.7% of deaths 
among women, and are the fourth most common 
cause of death by cancer in both men and women. 
The average age at onset is about 69 in men and 
76 in women. 
Risk factors
Tobacco and alcohol are under discussion as risk 
factors, as is a diet that is rich in animal fats. Over-
weight also has a disadvantageous effect. Risk can 
be reduced by a diet that is rich in vegetables and 
fruit. Inflammations of the pancreas and diabetes 
mellitus are also discussed as risk factors, albeit 
controversially. A small proportion of patients 
seem to be affected by a family-related increase 
in risk. Pancreatic cancer and other tumours are 
observed in families affected by genetically deter-
mined, so-called cancer syndromes.
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Figure 3 6 1
Estimated age-specific incidence in Germany in 2004, ICD-10 C25
New cases per 100,000 by age groups
Figure 3 6 2
Age-standardized incidence rates in Germany in 2002 according to the RKI's 1980 – 2002 estimates,  
and in 2004 according to the RKI's 1980 – 2004 estimates, compared internationally, ICD-10 C25
Incidence per 100,000 (World Standard)
Source: Globocan estimate 2002, the RKI's 2002 and 2004 estimates for Germany
ICD-10 C25     Cancer in Germany
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Incidence Mortality Incidence  Mortality 
Men        Women
Age in years Men Women
Incidence Mortality Incidence Mortality
under 15 0.0 0.0 0.0 0.0
15 to under 35 0.1 0.1 0.0 0.0
35 to under 40 1.1 0.8 0.5 0.5
40 to under 45 2.4 2.0 1.8 1.3
45 to under 50 5.7 5.8 3.6 2.6
50 to under 55 14.5 12.6 6.1 6.5
55 to under 60 24.6 22.0 12.9 11.2
60 to under 65 37.7 35.3 24.0 20.2
65 to under 70 48.0 51.2 29.4 32.1
70 to under 75 63.7 65.5 48.9 45.9
75 to under 80 80.6 89.8 65.3 66.7
80 to under 85 91.9 102.7 88.4 89.3
85 and older 114.0 117.4 103.5 111.2
Crude rate 15.7 15.9 15.7 15.6
Stand. rate (European standard) 12.6 12.6 8.7 8.4
Table 3 6 1
Incidence and mortality by age group in Germany in 2004, ICD-10 C25
Cases/deaths per 100,000 by age groups
Figure 3 6 3
Age-standardized incidence and mortality in Germany, 1980 – 2004, ICD-10 C25
Cases/deaths per 100,000 (European Standard)
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cases DCO casesless than 90% registration rate: casesat least 90% registration: 
Region Men Women
Crude rate % DCO Stand  rate* Crude rate % DCO Stand  rate*
Baden-Württemberg registry currently being developed
Bavaria 16.4 41 13.5 16.0 50 9.4
Berlin 16.0 43 14.0 15.1 54 9.0
Brandenburg 18.1 31 14.8 16.2 39 9.3
Bremen 17.5 22 13.4 15.8 31 7.6
Hamburg 15.4 17 12.9 15.5 21 8.7
Hesse (Darmstadt admin. dist.) 16.6 71 13.3 15.6 70 9.0
Mecklenburg-Western Pomerania 15.5 17 12.7 14.5 26 8.6
Lower Saxony 16.2 32 12.8 16.4 42 9.1
North Rhine-Westphalia (Münster admin. dist.) 15.1 23 13.0 14.7 24 8.4
Rhineland-Palatinate 15.6 41 12.1 16.6 49 9.0
Saarland 15.6 10 11.7 17.0 26 8.4
Saxony 18.5 32 13.9 18.1 37 9.2
Saxony-Anhalt 15.8 44 11.9 15.8 54 8.3
Schleswig-Holstein 18.1 42 13.8 16.6 48 9.5
Thuringia 16.0 40 12.7 16.3 44 9.0
Germany, estimated 15 5 15 12 6 15 6 21 8 7
                                                                                                      — at least 90% registration     —  less than 90% registration rate
Figure 3 6 4
Registered age-standardized incidence in the regions of Germany, 2003 – 2004, ICD-10 C25
New cases per 100,000 (European Standard)
Table 3 6 2
Registered incidence in the regions of Germany, 2003 – 2004, ICD-10 C25
New cases per 100,000 (*European Standard)
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Trends
Incidence in men has been decreasing since the 
1980s, while mortality has only been falling sig-
nificantly since about 1990. Both incidence and 
mortality due to laryngeal cancer in women has 
remained largely unchanged since the early 1990s, 
after increasing during the 1980s.
Survival
The relative 5-year survival rates for laryngeal 
cancer are about 61% among men and 62% in 
women.
Prevalence
Laryngeal cancer is the most common malignant 
tumour in the head/neck region; men are affected 
much more frequently than women. In men, 
laryngeal cancer accounts for 1.3% of all cancers; 
in women, the figure is only 0.2%. About 3,000 
men and 400 women a year are diagnosed with 
laryngeal cancer in Germany. On average, men 
and women tend to develop the disease at the age 
of 64, about five years earlier than in the case of all 
cancer sites. The average age of death is about 66 
in men and 69 in women. 
Risk factors
Smoking is the most important risk factor in 
the development of laryngeal cancer. The risk 
increases with the number of cigarettes smoked, 
and the combination with alcohol consumption is 
particularly harmful. This applies especially if the 
person concerned does not eat enough fruit and, 
perhaps, vegetables. There is also a known asso-
ciation between tumours of the larynx and work-
related exposure to a number of substances, for 
example asbestos, nickel or polycyclic aromatic 
hydrocarbons. These days, contact with these 
harmful substances should be excluded by pre-
ventive measures wherever possible. In Germany, 
laryngeal carcinoma can be recognized as an occu-
pational disease if the person concerned had to 
work with asbestos in the past. 
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Figure 3 7 1
Estimated age-specific incidence in Germany in 2004, ICD-10 C32
New cases per 100,000 by age groups
Figure 3 7 2
Age-standardized incidence rates in Germany in 2002 according to the RKI's 1980 – 2002 estimates,  
and in 2004 according to the RKI's 1980 – 2004 estimates, compared internationally, ICD-10 C32
Incidence per 100,000 (World Standard)
Source: Globocan estimate 2002, the RKI's 2002 and 2004 estimates for Germany
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Incidence Mortality Incidence  Mortality 
Men        Women
Age in years Men Women
Incidence Mortality Incidence Mortality
under 15 0.0 0.0 0.0 0.0
15 to under 35 0.0 0.0 0.0 0.0
35 to under 40 0.5 0.1 0.2 0.0
40 to under 45 2.3 0.7 0.3 0.0
45 to under 50 6.0 2.4 1.1 0.2
50 to under 55 14.2 5.1 1.6 0.4
55 to under 60 17.4 6.2 2.8 1.0
60 to under 65 20.1 9.3 2.0 0.8
65 to under 70 23.9 9.6 2.3 0.9
70 to under 75 24.5 12.4 2.3 0.9
75 to under 80 22.2 11.3 2.1 1.3
80 to under 85 22.3 12.7 1.5 1.1
85 and older 10.6 17.7 1.2 2.1
Crude rate 7.4 3.3 0.9 0.4
Stand. rate (European standard) 6.1 2.7 0.7 0.3
Cancer in Germany     Larynx
Table 3 7 1
Incidence and mortality by age group in Germany in 2004, ICD-10 C32
Cases/deaths per 100,000 by age groups
Figure 3 7 3
Age-standardized incidence and mortality in Germany, 1980 – 2004, ICD-10 C32
Cases/deaths per 100,000 (European Standard)
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Region Men Women
Crude rate % DCO Stand  rate* Crude rate % DCO Stand  rate*
Baden-Württemberg registry currently being developed
Bavaria 7.2 15 6.2 0.9 22 0.7
Berlin 6.4 21 5.6 1.1 32 0.8
Brandenburg 9.0 7 7.0 0.8 14 0.6
Bremen 11.4 10 9.5 1.6 0 1.2
Hamburg 6.6 4 5.8 1.5 7 1.1
Hesse (Darmstadt admin. dist.) 6.1 55 5.1 0.7 60 0.4
Mecklenburg-Western Pomerania 9.1 3 7.5 0.8 0 0.7
Lower Saxony 10.3 22 8.3 1.1 30 0.8
North Rhine-Westphalia (Münster admin. dist.) 6.3 12 5.6 1.1 17 0.8
Rhineland-Palatinate 8.9 23 7.2 0.9 34 0.6
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Thuringia 8.0 6 6.3 0.7 6 0.5
Germany, estimated 7 5 2 6 2 0 9 0 0 7
                                                                                                       — at least 90% registration     —  less than 90% registration rate
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Figure 3 7 4
Registered age-standardized incidence in the regions of Germany, 2003 – 2004, ICD-10 C32
New cases per 100,000 (European Standard)
Table 3 7 2
Registered incidence in the regions of Germany, 2003 – 2004, ICD-10 C32
New cases per 100,000 (*European Standard)
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Trends
There has been a marked decline in incidence 
and mortality due to lung cancer in men since the 
1990s. Among women, however, both incidence 
and mortality continue to rise. These develop-
ments in Germany reflect the same trends as in 
other European industrialized nations. The differ-
ences in incidence and mortality trends between 
men and women are attributed to smoking hab-
its.
Survival
The relative 5-year survival rates for patients with 
lung cancer are about 15% among men and 18% 
among women. As in the case of cancer in gen-
eral, the survival rates differ markedly according 
to the stage of the disease. During the local stage, 
the 5-year survival rates are above 50%; however, 
this falls to only 5% once remote metastases have 
formed. The histological type of tumour also has 
an influence on survival. For example, the survival 
rate is lower in the case of small-cell carcinomas 
compared to non-small-cell carcinomas. Overall, 
lung cancer still is one of the types with the most 
unfavourable prognoses.
Prevalence
Lung cancer is the third most common cancer site 
among both men and women in Germany. The 
approx. 33,000 new cases of lung cancer every 
year correspond to 14.3% of all new cancer cases in 
men. Among women, lung cancer now accounts 
for 6.4% of all malignant neoplasms with about 
13,200 new cases a year. Because the prognosis 
remains poor (see Survival), the proportion of all 
cancer-related deaths that are caused by lung can-
cer is especially marked at 26.0% in men (high-
est percentage) and 11.2% in women (third highest 
percentage). The average age at onset is about 68 
among both men and women and corresponds 
approximately to the age at diagnosis for all can-
cer sites.
Risk factors
Lung cancer is one of the malignant tumours 
whose main risk factor has been known for a long 
time. Up to 90% of lung cancer cases in men and 
currently up to 60% of cases in women can be 
attributed to active smoking. The risk of lung can-
cer rises with the number of "pack years", i.e. the 
number of cigarette packs (à 20 cigarettes) a per-
son smokes per day, multiplied by the number of 
years s/he smoked. The depth of inhalation and 
the concentration of tar and nicotine per cigarette 
are also relevant. Risk declines among former 
smokers, the longer ago the person gave up smok-
ing. Passive smoking also involves an increased 
risk. A regionally high level of radon radiation in 
residential houses also affects lung cancer risk. 
A comparatively small proportion of all lung can-
cer cases are attributed to occupational exposure 
to various carcinogenic materials (e.g. asbestos, 
ionizing radiation/radon, types of quartz dust and 
the silicosis it causes). Synergistic effects involving 
harmful substances (e.g. asbestos) and smoking 
have been proven. Eating a lot of fruit has a pro-
tective effect. The frequent consumption of veg-
etables also has a favourable effect on risk among 
smokers, although this does not by any means off-
set their increased risk.
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Figure 3 8 1
Estimated age-specific incidence in Germany in 2004, ICD-10 C33, C34
New cases per 100,000 by age groups
Figure 3 8 2
Age-standardized incidence rates in Germany in 2002 according to the RKI's 1980 – 2002 estimates,  
and in 2004 according to the RKI's 1980 – 2004 estimates, compared internationally, ICD-10 C33, C34
Incidence per 100,000 (World Standard)
Source: Globocan estimate 2002, the RKI's 2002 and 2004 estimates for Germany
ICD-10 C33, C34     Cancer in Germany
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Incidence Mortality Incidence  Mortality 
Men        Women
Age in years Men Women
Incidence Mortality Incidence Mortality
under 15 0.0 0.0 0.0 0.0
15 to under 35 0.3 0.3 0.4 0.3
35 to under 40 3.4 2.5 3.0 1.6
40 to under 45 12.4 8.9 11.7 5.6
45 to under 50 32.9 24.7 20.3 15.9
50 to under 55 69.4 54.7 41.4 25.9
55 to under 60 139.3 100.6 60.2 42.4
60 to under 65 192.2 163.8 63.9 50.4
65 to under 70 277.0 233.2 73.8 57.2
70 to under 75 384.0 339.5 99.0 78.3
75 to under 80 415.9 412.5 96.2 94.4
80 to under 85 396.1 427.4 93.4 99.7
85 and older 321.6 321.5 73.0 92.6
Crude rate 81.4 71.4 31.3 26.2
Stand. rate (European standard) 64.4 55.9 21.8 17.0
Cancer in Germany     Lung
Table 3 8 1
Incidence and mortality by age group in Germany in 2004, ICD-10 C33, C34
Cases/deaths per 100,000 by age groups
Figure 3 8 3
Age-standardized incidence and mortality in Germany, 1980 – 2004, ICD-10 C33, C34
Cases/deaths per 100,000 (European Standard)
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Figure 3 8 4
Registered age-standardized incidence in the regions of Germany, 2003 – 2004, ICD-10 C33, C34
New cases per 100,000 (European Standard)
Table 3 8 2
Registered incidence in the regions of Germany, 2003 – 2004, ICD-10 C033, C34
New cases per 100,000 (*European Standard)
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Trends
The number of people diagnosed with malignant 
melanoma of the skin has increased considerably 
over the last three decades. The incidence rates 
have more than tripled since 1980. By contrast, no 
substantial changes have been observed in mor-
tality since the 1970s. The increase in melanoma 
frequency has been steeper, mortality lower, and 
incidence rates higher among women, especially 
younger women, than among men. Malignant 
melanomas have also been diagnosed more often 
at earlier stages. Possible explanations could be 
the improved health education of the population, 
and health professionals paying more attention to 
melanoma-like lesions. Malignant melanoma of 
the skin is particularly suitable for early diagnosis 
because of its location on the body's surface.
Survival
For women with malignant melanoma of the skin, 
the relative 5-year survival rate is 88%, for men 
84%. As in the case of other cancers, the survival 
prospects are much worse after metastasization 
has occurred.
Prevalence
About 14,900 people are diagnosed with malig-
nant melanoma of the skin in Germany every year. 
Approx. 8,400 of these are women, 6,500 men. 
Malignant melanoma thus accounts for 4.1% of 
all malignant neoplasms among women, but only 
2.8% among men in Germany. It causes about 1% 
of all cancer-related deaths in both sexes. Most 
malignant melanomas develop from pigment cells 
of the skin (black skin cancer). Other melanoma 
manifestations – e.g. of the mucous membranes, 
the choroid of the eye or the meninges – are cate-
gorized by the ICD as malignant neoplasms of the 
affected organ, for example the eye. Other malig-
nant neoplasms of the skin (e.g. basal cell carci-
nomas, which generally do not metastasize, and 
spinaliomas) are much more common overall, but 
cause few cancer-related deaths. Since it is diffi-
cult to ensure their complete registration, they are 
not discussed in this brochure. Relevant incidence 
rates of malignant melanoma can be observed as 
early as the age of 20. The average age at onset 
is comparatively low: 63 in men and approx. 57 
in women. The average age of death is about 68 
among men and 72 among women.
Risk factors
Risk factors include a large number of pigmenta-
tion marks (acquired and congenital naevi, espe-
cially dysplastic forms), a light skin type and a 
genetic disposition (when there is familial clus-
tering). Although no dosage/effect relationship 
has been defined up to now, intense exposure to 
the sun resulting in sunburn, especially in child-
hood, and exposure to artificial UV radiation are 
regarded as potential triggers. Other factors, e.g. 
certain chemicals, drugs or the influence of preg-
nancy, are the subject of very controversial discus-
sion.
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Figure 3 9 1
Estimated age-specific incidence in Germany in 2004, ICD-10 C43
New cases per 100,000 by age groups
Figure 3 9 2
Age-standardized incidence rates in Germany in 2002 according to the RKI's 1980 – 2002 estimates,  
and in 2004 according to the RKI's 1980 – 2004 estimates, compared internationally, ICD-10 C43
Incidence per 100,000 (World Standard)
Source: Globocan estimate 2002, the RKI's 2002 and 2004 estimates for Germany
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Incidence Mortality Incidence  Mortality 
Men        Women
Age in years Men Women
Incidence Mortality Incidence Mortality
under 15 0.0 0.0 0.0 0.0
15 to under 35 4.1 0.3 12.1 0.2
35 to under 40 10.0 0.9 20.6 0.7
40 to under 45 11.3 1.4 21.0 1.2
45 to under 50 13.9 2.0 20.5 2.1
50 to under 55 18.2 2.7 24.7 1.8
55 to under 60 27.6 4.5 31.8 2.6
60 to under 65 36.3 6.1 30.5 3.6
65 to under 70 43.7 8.8 30.7 3.9
70 to under 75 42.5 10.9 31.5 6.6
75 to under 80 49.4 15.5 35.2 7.2
80 to under 85 57.6 18.6 34.9 10.2
85 and older 50.6 18.9 31.9 16.0
Crude rate 16.2 3.1 19.9 2.5
Stand. rate (European standard) 13.5 2.5 16.5 1.6
Cancer in Germany     Malignant melanoma of the skin
Table 3 9 1
Incidence and mortality by age group in Germany in 2004, ICD-10 C43
Cases/deaths per 100,000 by age groups
Figure 3 9 3
Age-standardized incidence and mortality in Germany, 1980 – 2004, ICD-10 C43
Cases/deaths per 100,000 (European Standard)
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Bavaria 17.1 5 10.6 16.9 5 10.2
Berlin 11.3 5 6.8 9.4 6 5.4
Brandenburg 11.3 1 6.6 12.2 3 7.2
Bremen 16.8 4 8.9 10.2 3 5.5
Hamburg 14.5 4 8.6 17.3 2 10.4
Hesse (Darmstadt admin. dist.) 11.4 13 7.0 10.8 13 6.6
Mecklenburg-Western Pomerania 12.5 6 8.1 11.0 3 6.1
Lower Saxony 18.2 7 11.2 19.4 7 12.3
North Rhine-Westphalia (Münster admin. dist.) 13.1 5 8.3 12.7 4 9.4
Rhineland-Palatinate 16.2 2 9.5 19.3 2 12.2
Saarland 14.2 0 8.2 16.7 1 10.2
Saxony 14.6 4 8.5 12.9 2 7.0
Saxony-Anhalt 12.5 5 7.3 13.8 2 7.8
Schleswig-Holstein 24.0 5 14.6 26.1 4 16.9
Thuringia 16.3 2 9.4 14.1 4 8.7
Germany, estimated 15 7 1 13 2 19 4 0 16 1
                                                                                                      — at least 90% registration     —  less than 90% registration rate
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Figure 3 9 4
Registered age-standardized incidence in the regions of Germany, 2003 – 2004, ICD-10 C43
New cases per 100,000 (European Standard)
Table 3 9 2
Registered incidence in the regions of Germany, 2003 – 2004, ICD-10 C43
New cases per 100,000 (*European Standard)
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the population-based cancer registries to provide 
information both on the number of breast-cancer 
cases that have occurred between two screening 
examinations (interval cancers) and on changes 
in the stage distribution of breast cancer at diag-
nosis and in mortality trends associated with 
mammographic screening. In this way it will be 
possible to observe the expected and hoped-for 
changes in the incidence of breast cancer in the 
female population, and to optimize the quality of 
the screening programme offered to the women 
participating.
Trends
Breast cancer has been more thoroughly registe-
red by the population-based cancer registries than 
any other cancer site and thus offers a good data 
base for estimating incidence Germany-wide. 
Overall, breast-cancer incidence in Germany has 
been rising continuously since 1980, while the 
mortality rate has been falling slightly since the 
mid-1990s. 
Survival
The mean relative 5-year survival rate for breast-
cancer patients is currently approx. 81%.
Prevalence
Over 57,000 women in Germany are currently dia-
gnosed with breast cancer every year. Breast cancer 
is the most common form of cancer in women and 
accounts for well over a quarter (27.8%) of all can-
cers among women. The average age at onset is 63, 
six years below the average for all cancer sites.
Risk factors
An early first menstruation (menarche), childles-
sness, a late first birth and a late menopause (cli-
macteric) are associated with an increased risk of 
breast cancer. On the other hand, giving birth at a 
young age, several births and longer lactation peri-
ods seem to reduce breast-cancer risk. Ovulation 
inhibitors containing oestrogen and progesterone 
(the "Pill") slightly increase the risk of breast cancer, 
an effect that disappears ten years after the woman 
stops using the Pill. However, they have a favou-
rable effect on the risk of ovarian cancer and cancer 
originating in the lining of the uterus (endometrial 
carcinoma). Scientific studies show that hormone 
therapy with oestrogens – especially with a combi-
nation of oestrogens and gestagens – increases the 
risk of developing breast cancer during and after 
the menopause. Many studies have observed an 
increase in risk due to overweight, lack of exercise, 
and to some extent regular consumption of alcohol, 
whereas regular physical activity and sport have a 
favourable influence. Breast cancer in close relati-
ves increases the risk of developing the disease. It 
seems likely that only a small proportion of breast-
cancer patients have inheritable genetic modifica-
tions associated with an increased risk. Some (but 
by no means all) of the genetic modifications invol-
ved, and their effects, are known. Connections have 
also been observed with family clusters of ovarian 
cancer.
The joint self-governing body of physicians 
and health-insurance funds – in cooperation 
with the federal states – is currently building up 
a structured and quality-assured mammographic 
screening programme by individual invitation for 
all women between the ages of 50 and 69 for the 
early detection of breast cancer. The plan is to use 
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Figure 3 10 1
Estimated age-specific incidence in Germany in 2004, ICD-10 C43
New cases per 100,000 by age groups
Figure 3 10 2
Age-standardized incidence rates in Germany in 2002 according to the RKI's 1980 – 2002 estimates,  
and in 2004 according to the RKI's 1980 – 2004 estimates, compared internationally, ICD-10 C43
Incidence per 100,000 (World Standard)
Source: Globocan estimate 2002, the RKI's 2002 and 2004 estimates for Germany
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Incidence  Mortality 
Women
Age in years Women
Incidence Mortality
under 15 0.0 0.0
15 to under 35 9.0 1.0
35 to under 40 53.0 7.0
40 to under 45 105.4 15.4
45 to under 50 167.9 25.5
50 to under 55 221.1 39.7
55 to under 60 286.9 58.3
60 to under 65 299.1 75.8
65 to under 70 303.2 89.7
70 to under 75 275.9 101.7
75 to under 80 283.7 129.2
80 to under 85 278.2 162.2
85 and older 231.8 223.5
Crude rate 135.8 41.7
Stand. rate (European standard) 104.2 26.8
Cancer in Germany     Breast in women
Table 3 10 1
Incidence and mortality by age group in Germany in 2004, ICD-10 C50
Cases/deaths per 100,000 by age groups
Figure 3 10 3
Age-standardized incidence and mortality in Germany, 1980 – 2004, ICD-10 C50
Cases/deaths per 100,000 (European Standard)
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Saxony-Anhalt
            Women
cases DCO casesless than 90% registration rate: casesat least 90% registration: 
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Crude rate % DCO Stand  rate*
Baden-Württemberg registry currently being developed
Bavaria 143.2 14 108.1
Berlin 116.8 18 85.8
Brandenburg 123.9 5 89.2
Bremen 169.1 5 120.7
Hamburg 135.2 5 104.5
Hesse (Darmstadt admin. dist.) 115.3 29 83.4
Mecklenburg-Western Pomerania 118.7 4 87.5
Lower Saxony 173.7 17 126.3
North Rhine-Westphalia (Münster admin. dist.) 127.0 5 98.5
Rhineland-Palatinate 148.9 14 107.9
Saarland 153.3 2 110.0
Saxony 129.1 5 86.1
Saxony-Anhalt 117.9 11 79.4
Schleswig-Holstein 182.5 14 133.6
Thuringia 127.7 7 88.4
Germany, estimated 135 0 1 103 9
                                                                                                      — at least 90% registration     —  less than 90% registration rate
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Figure 3 10 4
Registered age-standardized incidence in the regions of Germany, 2003 – 2004, ICD-10 C50
New cases per 100,000 (European Standard)
Table 3 10 2
Registered incidence in the regions of Germany, 2003 – 2004, ICD-10 C50
New cases per 100,000 (*European Standard)
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Trends
Since the 1970s the incidence of cervical cancer 
had been declining markedly in Germany. In the 
last few years the incidence of invasive cervical can-
cer has been virtually constant. The mortality rates 
from cervical cancer have continued to decrease, 
also over the last few years. Much of this decline 
has been due to the statutory cancer screening pro-
gramme, which makes it possible to diagnose cer-
vical cancer during its preliminary stages. Timely 
treatment can then prevent the development of the 
complete (invasive) carcinoma.
Survival
The relative 5-year survival rate in the case of fully 
developed cancer of the cervix (invasive carcinoma) 
is about 61%.
Prevalence
About 6,200 cases of cervical cancer currently occur 
in Germany every year. This corresponds to 3% of 
all cancer cases and accounts for 1.7% of all can-
cer-related deaths in women. The age-specific inci-
dence rates show two separate age peaks. The first 
occurs in the 35 – 54 age group, followed by another 
increase that starts around the age of 65. The mean 
age at diagnosis is approx. 51 years, 18 years younger 
than for all cancer sites. In the 1970s cervical carci-
noma was the most common type of cancer of the 
female genital organs. It is currently the eleventh 
most frequent cancer among women.
Risk factors
Today there is no doubt that cervical cancer regu-
larly develops from a persistent infection with cer-
tain strains of human papillomaviruses (HPVs), 
often acquired decades earlier. The HPV infection, 
not the cancer, can be sexually transmitted. Most 
women are infected with HPV in the course of 
their lives; however, the infection only persists in 
a small percentage of them. Sexual intercourse at 
an early age, unprotected sexual intercourse with 
alternating partners, and a high number of births 
are associated with a higher risk of developing 
the disease. Other pathogens of sexually trans-
mitted diseases – e.g. herpes simplex viruses or 
chlamydia – are regarded as potential co-factors in 
carcinogenesis. Further studies will be required 
to determine whether the slight increase in risk 
observed in women currently using oral contra-
ceptives containing oestrogens and gestagens (the 
"Pill") is real, or rather an indication of heightened 
sexual activity. Smoking and passive smoking and 
a poor diet are regarded as co-factors. 
Since the 1970s women above the age of 20 
have been offered a colposcopic examination and a 
Pap smear (cervical smear examination introduced 
by Papanicolaou). Since then a decrease has been 
observed in cervical carcinoma incidence and mor-
tality. Since mid-2007 statutory health insurance 
has been offering all girls between the ages of 12 
and 17 a three-dose vaccination against high-risk 
human papillomavirus strains (HPV). 
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Figure 3 11 1
Estimated age-specific incidence in Germany in 2004, ICD-10 C53
New cases per 100,000 by age groups
Figure 3 11 2
Age-standardized incidence rates in Germany in 2002 according to the RKI's 1980 – 2002 estimates,  
and in 2004 according to the RKI's 1980 – 2004 estimates, compared internationally, ICD-10 C53
Incidence per 100,000 (World Standard)
Source: Globocan estimate 2002, the RKI's 2002 and 2004 estimates for Germany
ICD-10 C53     Cancer in Germany
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Incidence  Mortality 
Women
Age in years Women
Incidence Mortality
under 15 0.0 0.0
15 to under 35 4.9 0.2
35 to under 40 23.5 1.8
40 to under 45 26.3 3.2
45 to under 50 26.3 4.6
50 to under 55 29.1 5.9
55 to under 60 16.6 6.5
60 to under 65 13.4 6.1
65 to under 70 14.6 6.8
70 to under 75 19.9 8.0
75 to under 80 16.7 9.6
80 to under 85 20.8 12.4
85 and older 26.9 14.8
Crude rate 14.7 3.9
Stand. rate (European standard) 12.4 2.8
Cancer in Germany     Cervix
Table 3 11 1
Incidence and mortality by age group in Germany in 2004, ICD-10 C53
Cases/deaths per 100,000 by age groups
Figure 3 11 3
Age-standardized incidence and mortality in Germany, 1980 – 2004, ICD-10 C53
Cases/deaths per 100,000 (European Standard)
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Bavaria 10.5 12 8.6
Berlin 13.6 15 11.0
Brandenburg 14.2 5 11.7
Bremen 13.2 2 10.0
Hamburg 11.7 2 9.8
Hesse (Darmstadt admin. dist.) 8.6 31 6.9
Mecklenburg-Western Pomerania 12.2 5 9.9
Lower Saxony 12.3 14 9.9
North Rhine-Westphalia (Münster admin. dist.) 8.6 7 7.0
Rhineland-Palatinate 9.5 11 7.7
Saarland 13.5 0 11.0
Saxony 14.7 4 11.8
Saxony-Anhalt 13.9 7 10.7
Schleswig-Holstein 14.7 11 12.0
Thuringia 13.9 4 11.3
Germany, estimated 14 7 1 12 4
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Figure 3 11 4
Registered age-standardized incidence in the regions of Germany, 2003 – 2004, ICD-10 C53
New cases per 100,000 (European Standard)
Table 3 11 2
Registered incidence in the regions of Germany, 2003 – 2004, ICD-10 C53
New cases per 100,000 (*European Standard)
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Trends
The incidence rates have been decreasing slightly 
since the mid-1990s, following a slight increase 
during the 1980s. As in the case of cervical can-
cer, mortality due to cancer of the uterus corpus 
is decreasing.
Survival
With a relative 5-year survival rate of approx. 82%, 
corpus carcinomas can be ranked among the can-
cer sites with a favourable prognosis.
Prevalence
Most cancers of the uterus corpus (corpus carcino-
mas) are endometrial carcinomas, i.e. they develop 
in the lining of the uterus (endometrium). With 
about 11,700 new cases a year, uterine cancer repre-
sents the fourth most common cancer site overall 
among women and the most common site of the 
female genital organs. It accounts for 5.7% of all 
malignant neoplasms. Thanks to the good progno-
sis, it causes a much lower percentage of all can-
cer-related deaths: 2.6%. The average age at onset 
is approx. 68 years, about the same as with cancer 
sites in general.
Risk factors
Hormonal influences over many years are regarded 
as the primary risk factor for endometrial cor-
pus carcinomas. This applies on the one hand to 
heightened exposure to the body's own (internal) 
oestrogen, which can be directly related to over-
weight (obesity), or childlessness, or be a result 
of early menarche, late menopause or long cycles 
without ovulation (for example in the case of poly-
cystic ovaries). On the other hand, the "Pill", i.e. 
an oral contraceptive, provides protection against 
the development of corpus carcinomas, especially 
when oestrogen/gestagen combinations are used. 
However, this slightly increases the risk of breast 
cancer, as described in section 3.10. It is possible 
that the administration of oestrogens as a mono-
therapy for climacteric complaints increases the 
risk not only of breast cancer, but also of endome-
trial carcinoma, which can be prevented by the 
additional administration of progesterone.
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Figure 3 12 1
Estimated age-specific incidence in Germany in 2004, ICD-10 C54, C55
New cases per 100,000 by age groups
Figure 3 12 2
Age-standardized incidence rates in Germany in 2002 according to the RKI's 1980 – 2002 estimates,  
and in 2004 according to the RKI's 1980 – 2004 estimates, compared internationally, ICD-10 C54, C55
Incidence per 100,000 (World Standard)
Source: Globocan estimate 2002, the RKI's 2002 and 2004 estimates for Germany
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Incidence  Mortality 
Women
Age in years Women
Incidence Mortality
under 15 0.0 0.0
15 to under 35 1.1 0.0
35 to under 40 5.6 0.5
40 to under 45 4.3 0.5
45 to under 50 9.2 1.3
50 to under 55 31.9 3.2
55 to under 60 56.8 5.2
60 to under 65 65.1 8.6
65 to under 70 80.1 12.2
70 to under 75 80.1 17.1
75 to under 80 86.3 23.4
80 to under 85 76.6 32.3
85 and older 61.4 45.0
Crude rate 27.8 6.1
Stand. rate (European standard) 19.3 3.4
Cancer in Germany     Uterus (corpus)
Table 3 12 1
Incidence and mortality by age group in Germany in 2004, ICD-10 C54, C55
Cases/deaths per 100,000 by age groups
Figure 3 12 3
Age-standardized incidence and mortality in Germany, 1980 – 2004, ICD-10 C54, C55
Cases/deaths per 100,000 (European Standard)
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cases DCO casesless than 90% registration rate: casesat least 90% registration: 
Region Women
Crude rate % DCO Stand  rate*
Baden-Württemberg registry currently being developed
Bavaria 25.1 13 17.3
Berlin 15.3 16 10.4
Brandenburg 29.6 5 19.1
Bremen 29.5 3 19.2
Hamburg 18.3 4 12.4
Hesse (Darmstadt admin. dist.) 14.7 31 9.6
Mecklenburg-Western Pomerania 29.4 4 19.1
Lower Saxony 28.4 16 18.6
North Rhine-Westphalia (Münster admin. dist.) 23.1 5 16.7
Rhineland-Palatinate 25.8 11 16.9
Saarland 28.4 1 17.4
Saxony 33.8 4 20.0
Saxony-Anhalt 27.4 9 16.3
Schleswig-Holstein 25.8 10 16.7
Thuringia 28.2 5 17.7
Germany, estimated 27 7 1 19 3
                                                                                                      — at least 90% registration     —  less than 90% registration rate
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Figure 3 12 4
Registered age-standardized incidence in the regions of Germany, 2003 – 2004, ICD-10 C54, C55
New cases per 100,000 (European Standard)
Table 3 12 2
Registered incidence in the regions of Germany, 2003 – 2004, ICD-10 C54, C55
New cases per 100,000 (*European Standard)
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Trends
The incidence rates of ovarian cancer have 
remained virtually constant in Germany over the 
last 20 to 30 years. By contrast, mortality rates 
have fallen more markedly over time since the 
late 1980s. Hence, the epidemiological similarity 
between this cancer and uterine corpus cancer is 
also shown in the trend.
Survival
The survival prospects of patients with ovarian 
cancer are rather poor compared to other cancers 
of the female genital organs, although they have 
improved slightly over time. The relative 5-year 
survival rate is currently about 47%.
Prevalence
According to the latest results of the RKI estimate 
based on the cancer registration data up to 2004, 
approx. 9,660 women develop cancer of the ova-
ries every year in Germany. This disease thus 
accounts for 4.7% of all malignant neoplasms in 
women. Nevertheless, due to a worse prognosis 
mortality, at almost 5,500 cases per annum (5.6% 
of all cancer-related deaths) is higher than the fig-
ure for all uterine cancers. The age distribution is 
similar to that of uterine corpus cancer, although 
approx. 10% of all ovarian cancer cases affect 
women under the age of 45. These are mostly 
germ-cell tumours. The average age at diagnosis 
of the disease is between 67 and 68.
Risk factors
The risk of developing epithelial ovarian cancer 
seems to be associated with hormonal influences 
over many years. An early first menstruation, a late 
onset of the menopause, childlessness and short 
or even no lactation periods have an unfavourable 
effect. Hormonal ovulation inhibitors (the "Pill") 
provide protection against ovarian cancer; com-
bination preparations with oestrogens and gesta-
gens, however, increase the risk of breast cancer 
slightly. Genetic predispositions have been proven 
in several studies. Women whose first-degree rela-
tives have developed breast or ovarian cancer, or 
who have themselves already had breast, uterine 
corpus or colorectal cancer, are at greater risk of 
developing ovarian cancer.
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Figure 3 13 1
Estimated age-specific incidence in Germany in 2004, ICD-10 C56
New cases per 100,000 by age groups
Figure 3 13 2
Age-standardized incidence rates in Germany in 2002 according to the RKI's 1980 – 2002 estimates,  
and in 2004 according to the RKI's 1980 – 2004 estimates, compared internationally, ICD-10 C56
Incidence per 100,000 (World Standard)
Source: Globocan estimate 2002, the RKI's 2002 and 2004 estimates for Germany
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Incidence  Mortality 
Women
Age in years Women
Incidence Mortality
under 15 0.0 0.0
15 to under 35 3.1 0.3
35 to under 40 7.2 1.0
40 to under 45 12.0 2.6
45 to under 50 16.3 5.3
50 to under 55 27.3 9.1
55 to under 60 33.7 14.5
60 to under 65 43.2 23.6
65 to under 70 51.7 29.9
70 to under 75 54.5 40.5
75 to under 80 66.9 50.5
80 to under 85 80.3 59.4
85 and older 64.4 62.6
Crude rate 22.9 13.2
Stand. rate (European standard) 15.9 8.0
Cancer in Germany     Ovaries
Table 3 13 1
Incidence and mortality by age group in Germany in 2004, ICD-10 C56
Cases/deaths per 100,000 by age groups
Figure 3 13 3
Age-standardized incidence and mortality in Germany, 1980 – 2004, ICD-10 C56
Cases/deaths per 100,000 (European Standard)
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Bavaria 21.9 25 15.6
Berlin 16.6 32 11.9
Brandenburg 20.8 16 13.7
Bremen 24.3 4 16.4
Hamburg 20.6 10 14.6
Hesse (Darmstadt admin. dist.) 14.8 52 10.1
Mecklenburg-Western Pomerania 18.1 13 11.9
Lower Saxony 24.3 19 17.0
North Rhine-Westphalia (Münster admin. dist.) 21.9 10 15.5
Rhineland-Palatinate 21.2 26 14.6
Saarland 21.4 9 14.0
Saxony 22.1 13 13.5
Saxony-Anhalt 18.0 28 11.4
Schleswig-Holstein 24.4 23 16.2
Thuringia 19.1 18 12.9
Germany, estimated 22 9 4 16 0
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Figure 3 13 4
Registered age-standardized incidence in the regions of Germany, 2003 – 2004, ICD-10 C56
New cases per 100,000 (European Standard)
Table 3 13 2
Registered incidence in the regions of Germany, 2003 – 2004, ICD-10 C56
New cases per 100,000 (*European Standard)
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some areas over 50% of the carcinoma diagnoses 
made in reaction to a positive PSA test would oth-
erwise never have been made during the patient's 
lifetime. Men with an undiscovered prostate car-
cinoma would have died of another cause. Since it 
is not clear which of the carcinomas detected early 
in this way would ultimately have become symp-
tomatic later on, no one can predict whether an 
individual diagnosis of prostate cancer represents 
a needless overdiagnosis, or whether treatment 
would have been helpful.
Autopsy studies have long since revealed a 
high proportion of undiscovered, asymptomatic 
prostate carcinomas among men over 70, and 
especially over 80, that had had no influence on 
the life expectancy or quality of life of the people 
concerned. The prerequisite for adding the PSA 
test to the statutory cancer-screening programme 
is scientific proof of its benefit for the population, 
i.e. does it reduce prostate cancer mortality? Two 
major, randomized studies are currently being car-
ried out to measure this benefit; the results are 
expected in 2010. In Germany, the mortality rate 
from prostate cancer showed a slight increase from 
the early 1970s to the mid-1990s; the figure sub-
sequently fell back to the 1970s level. Ultimately, 
therefore, the mortality rates have remained almost 
unchanged since 1970.
Survival
The relative 5-year survival rate of patients with 
prostate cancer has improved markedly over the 
last few years and is now approx. 87%. In the case 
of prostate cancer diagnosed between 1984 and 
1998 it was 82%, albeit calculated according to a 
different method. The improvement was largely 
due to early diagnosis by screening. As far as the 
prognosis is concerned, a distinction must be made 
between slowly progressing forms and aggressive, 
metastasizing forms, which occur in greater pro-
portions among younger men (under 60).
Prevalence
In Germany, over 58,000 prostate carcinomas 
are currently diagnosed every year. At 25.4% this 
makes the prostate gland the most common site 
of malignant neoplasms in men. Prostate carci-
noma is the third most common cause of death 
among the fatal cancer sites, accounting for 10.1% 
of deaths. The average age at onset is approx. 69 
years, which corresponds roughly to the average 
age for all cancer sites. Even now only very few 
people are diagnosed before the age of 50.
Risk factors
Up to now the causes of prostate carcinoma and 
the factors affecting the progression of the disease 
are essentially unknown. A genetic predisposi-
tion is under discussion in the case of men who 
develop the disease at a young age; the differences 
in the frequency of prostate carcinoma in differ-
ent ethnic groups also points in this direction. 
Overweight, a high-fat and high-calorie diet, lack 
of exercise and smoking are under discussion as 
possible risk factors. 
Trends
Following a period characterized by slightly ris-
ing or constant incidence rates in the Saarland, 
a steep rise in rates has been observed since the 
late 1980s. The estimated incidence figures for 
Germany continued rising up to 2004. Indeed, 
the annual number of new cases of prostate car-
cinoma more than doubled in the course of eight 
years.
This increase can be largely attributed to the 
use of new diagnostic methods (e.g. testing for 
prostate-specific antigen (PSA)). The lower mean 
age at onset of the disease also indicates that diag-
noses are being made earlier. Without the PSA 
test, the majority of the prostate carcinomas diag-
nosed today would never have been detected, and 
the diagnostic clarification made necessary by 
positive results would never have been carried out 
during the patient's lifetime. It is estimated that in 
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Figure 3 14 1
Estimated age-specific incidence in Germany in 2004, ICD-10 C61
New cases per 100,000 by age groups
Figure 3 14 2
Age-standardized incidence rates in Germany in 2002 according to the RKI's 1980 – 2002 estimates,  
and in 2004 according to the RKI's 1980 – 2004 estimates, compared internationally, ICD-10 C61
Incidence per 100,000 (World Standard)
Source: Globocan estimate 2002, the RKI's 2002 and 2004 estimates for Germany
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Men        
Age in years Men
Incidence Mortality
under 15 0.0 0.0
15 to under 35 0.0 0.0
35 to under 40 0.0 0.0
40 to under 45 0.0 0.0
45 to under 50 13.6 1.2
50 to under 55 56.9 2.7
55 to under 60 200.1 11.0
60 to under 65 402.7 27.3
65 to under 70 587.1 57.8
70 to under 75 730.8 106.0
75 to under 80 758.5 207.0
80 to under 85 740.9 385.0
85 and older 694.0 640.4
Crude rate 145.2 27.6
Stand. rate (European standard) 112.0 22.2
Cancer in Germany     Prostate
Table 3 14 1
Incidence and mortality by age group in Germany in 2004, ICD-10 C61
Cases/deaths per 100,000 by age groups
Figure 3 14 3
Age-standardized incidence and mortality in Germany, 1980 – 2004, ICD-10 C61
Cases/deaths per 100,000 (European Standard)
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 Lower Saxony                                       
Schleswig-Holstein                                 
Saarland                          
Brandenburg                        
NRW (Münster dist.)                      
Bremen                      
Germany, estimated                      
Bavaria                     
   Rhineland-Palatinate                     
        Meckl.-Western Pom.                 
                     Hamburg                
Hesse (Darmstadt dist.)               
   Saxony              
Thuringia            
                 Saxony-Anhalt          
  Berlin 
 180 150 120 90 60 30 0
Men              
cases DCO casesless than 90% registration rate: casesat least 90% registration: 
Region Men
Crude rate % DCO Stand  rate*
Baden-Württemberg registry currently being developed
Bavaria 136.4 14 110.7
Berlin 72.7 24 64.3
Brandenburg 144.9 6 115.6
Bremen 152.8 8 112.1
Hamburg 121.3 7 99.0
Hesse (Darmstadt admin. dist.) 122.2 25 96.9
Mecklenburg-Western Pomerania 124.8 6 101.2
Lower Saxony 190.7 16 146.6
Nord Rhine-Westphalia (Münster admin. dist.) 140.2 6 114.2
Rhineland-Palatinate 144.7 14 110.2
Saarland 171.1 2 122.2
Saxony 133.1 9 95.4
Saxony-Anhalt 113.9 15 85.3
Schleswig-Holstein 184.2 11 137.3
Thuringia 114.5 15 89.8
Germany, estimated 142 4 2 111 1
                                                                                                      — at least 90% registration     —  less than 90% registration rate
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Figure 3 14 4
Registered age-standardized incidence in the regions of Germany, 2003 – 2004, ICD-10 C61
New cases per 100,000 (European Standard)
Table 3 14 2
Registered incidence in the regions of Germany, 2003 – 2004, ICD-10 C61
New cases per 100,000 (*European Standard)
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Trends
A rise in the incidence of testicular cancer and fall-
ing mortality rates have been observed for decades 
in Germany and the rest of Europe. Both trends 
continue. There is a consensus that the falling 
mortality rates are due to the successful use of cis-
platinum in the cytostatic treatment of testicular 
cancer.
Survival
With a relative 5-year survival rate of almost 100%, 
testicular cancer is one of the malignant neo-
plasms with the most favourable prognoses. 
Prevalence
About 4,750 men a year are currently diagnosed 
with testicular cancer in Germany. Since this cor-
responds to 2% of all malignant cancers in men, 
it means that testicular cancer is one of the rarer 
sites of cancer, causing only 0.2% of all cancer-
related deaths among men. There is an unusual 
age distribution in testicular cancer, with most 
cases occurring between the ages of 25 and 45. In 
this age group, testicular cancer is the most com-
mon malignant tumour among men. Less than a 
fifth of new cases are diagnosed in men over 45. 
The average age at onset is thus 37, the average 
age of death 45. 
Risk factors
Undescended testis (cryptorchism) is regarded as 
a confirmed risk factor for testicular cancer. Men 
who have already developed testicular cancer on 
one side are at increased risk of also developing a 
tumour on the initially healthy side. A small pro-
portion of people affected evidently have a genetic 
disposition (familial clustering), since the sons 
and brothers of patients with testicular cancer 
have a markedly increased risk of developing the 
disease. 
One hypothesis suggests that a predisposition 
for germ-cell tumours, which are the most com-
mon form in the testes, possibly already develops 
during the embryonic period from scattered cells 
that go through a malignant development during 
puberty. Up to now little is known about what has 
been causing the observed increase in incidence in 
recent decades. Research is currently concentrat-
ing on prenatal risk factors, among others. Several 
postnatal characteristics (early onset of puberty, 
gigantism and subfertility) are also under discus-
sion as possible risk factors.
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Figure 3 15 1
Estimated age-specific incidence in Germany in 2004, ICD-10 C62
New cases per 100,000 by age groups
Figure 3 15 2
Age-standardized incidence rates in Germany in 2002 according to the RKI's 1980 – 2002 estimates,  
and in 2004 according to the RKI's 1980 – 2004 estimates, compared internationally, ICD-10 C62
Incidence per 100,000 (World Standard)
Source: Globocan estimate 2002, the RKI's 2002 and 2004 estimates for Germany
ICD-10 C62     Cancer in Germany
76












Men        
Age in years Men
Incidence Mortality
under 15 0.1 0.0
15 to under 35 19.2 0.4
35 to under 40 30.1 0.8
40 to under 45 24.5 0.7
45 to under 50 12.5 0.6
50 to under 55 6.6 0.6
55 to under 60 3.1 0.2
60 to under 65 3.3 0.4
65 to under 70 1.7 0.3
70 to under 75 1.7 0.7
75 to under 80 2.2 0.5
80 to under 85 1.1 1.8
85 and older 0.8 3.0
Crude rate 11.8 0.5
Stand. rate (European standard) 11.1 0.4
Cancer in Germany     Testis
Table 3 15 1
Incidence and mortality by age group in Germany in 2004, ICD-10 C62
Cases/deaths per 100,000 by age groups
Figure 3 15 3
Age-standardized incidence and mortality in Germany, 1980 – 2004, ICD-10 C62
Cases/deaths per 100,000 (European Standard)
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Germany, estimated                               
Lower Saxony                             
Thuringia                        
        Meckl.-Western Pom.                       
Saxony                      
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Hesse (Darmstadt dist.)
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Men              
cases DCO casesless than 90% registration rate: casesat least 90% registration: 
Region Men
Crude rate % DCO Stand  rate*
Baden-Württemberg registry currently being developed
Bavaria 9.3 2 8.7
Berlin 6.0 4 5.1
Brandenburg 9.1 3 8.2
Bremen 8.1 2 7.4
Hamburg 9.7 1 8.4
Hesse (Darmstadt admin. dist.) 4.6 9 4.3
Mecklenburg-Western Pomerania 10.3 1 9.4
Lower Saxony 10.7 5 10.2
North Rhine-Westphalia (Münster admin. dist.) 9.3 1 8.7
Rhineland-Palatinate 9.0 5 8.7
Saarland 8.6 0 8.2
Saxony 9.8 1 9.1
Saxony-Anhalt 8.0 4 7.3
Schleswig-Holstein 11.5 3 11.0
Thuringia 10.3 2 9.4
Germany, estimated 11 6 0 10 9
                                                                                                      — at least 90% registration     —  less than 90% registration rate
ICD-10 C62     Cancer in Germany
Figure 3 15 4
Registered age-standardized incidence in the regions of Germany, 2003 – 2004, ICD-10 C62
New cases per 100,000 (European Standard)
Table 3 15 2
Registered incidence in the regions of Germany, 2003 – 2004, ICD-10 C62
New cases per 100,000 (*European Standard)
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Trends
The incidence rates for both sexes increased 
between 1980 and 2004 and almost doubled in 
men. The rates for men have always been higher 
than those for women, and the difference between 
the sexes has grown over the last few years. Mortal-
ity has declined slightly in both sexes since the mid-
1990s. A parallel development has been observed 
for years, again with higher rates for men. 
Survival
The average relative 5-year survival rate for men 
with kidney cancer is 66%; among women it is 
about 67%. It is known from clinical studies that, 
in the tumour stages T1 and T2, 80 to 90% of the 
patients survive the first five years after diagnosis. 
However, the survival rate falls below 10% once 
metastasis has occurred. 
Prevalence
The annual number of new cases of renal cancer 
in Germany is estimated at approx. 6,500 among 
women and 10,750 among men. 10% of these 
relate to carcinomas of the renal pelvis, the ureters 
and urethra. This brochure continues to categorize 
kidney cancers together with those of the effer-
ent urinary tract to describe the trend over time. 
Kidney cancer accounts for 4.7% of all cancers in 
men and 3.2% in women. It is one of the most fre-
quent causes of death from cancer (eleventh most 
common cause in women, sixth among men). The 
average age at onset is approx. 67 among men and 
almost 71 among women. 85% of malignant neo-
plasms of the kidney in adults are kidney-cell car-
cinomas (hypernephromas). By contrast, neph-
roblastomas (Wilms' tumours), sarcomas and 
lymphomas of the kidney are rare in adults.
Risk factors
There seems to be an association between over-
weight and kidney cancer, especially in women; 
in men, the decisive factor seems to be the type of 
fat distribution. A connection is made between an 
increased risk of kidney cancer on the one hand 
and smoking, passive smoking and the uncon-
trolled intake of painkillers containing phenace-
tin in particular – which are no longer used today 
– and the resultant damage to the kidneys on the 
other. Chronic renal insufficiency favours carcino-
genesis in general. Occupational risks related to 
exposure to kidney-damaging substances (e.g. 
halogen hydrocarbons, cadmium, etc.) are seen, 
although there is only an indirect association. Fam-
ily disposition is also among the known risk fac-
tors. Clear-cell renal-cell carcinomas, which occur 
in the context of the rare, hereditary Hippel-Lindau 
syndrome, are often multifocal (i.e. are seen in dif-
ferent places in the same organ at the same time) 
and occur more frequently at younger ages than 
kidney cancers not associated with genetic dispo-
sition.
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Figure 3 16 1
Estimated age-specific incidence in Germany in 2004, ICD-10 C64 – 66, C68
New cases per 100,000 by age groups
Figure 3 16 2
Age-standardized incidence rates in Germany in 2002 according to the RKI's 1980 – 2002 estimates,  
and in 2004 according to the RKI's 1980 – 2004 estimates, compared internationally, ICD-10 C64 – 66, C68
Incidence per 100,000 (World Standard)
Source: Globocan estimate 2002, the RKI's 2002 and 2004 estimates for Germany
ICD-10 C64 – 66, C68     Cancer in Germany
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Incidence Mortality Incidence  Mortality 
Men        Women
Age in years Men Women
Incidence Mortality Incidence Mortality
under 15 0.6 0.1 0.0 0.0
15 to under 35 0.6 0.1 0.6 0.1
35 to under 40 4.9 0.4 2.1 0.2
40 to under 45 7.6 1.2 2.7 0.7
45 to under 50 17.6 3.6 8.6 1.4
50 to under 55 29.8 5.9 12.7 2.0
55 to under 60 45.8 10.8 18.6 3.9
60 to under 65 67.9 19.3 28.5 6.7
65 to under 70 89.8 32.3 39.6 12.6
70 to under 75 110.0 46.5 50.4 20.4
75 to under 80 115.8 62.3 62.3 27.6
80 to under 85 91.3 80.9 58.4 36.3
85 and older 61.4 87.6 41.8 41.7
Crude rate 26.6 10.3 15.4 6.2
Stand. rate (European standard) 21.4 8.1 9.9 3.3
Cancer in Germany     Kidney and efferent urinary tract
Table 3 16 1
Incidence and mortality by age group in Germany in 2004, ICD-10 C64 – 66, C68
Cases/deaths per 100,000 by age groups
Figure 3 16 3
Age-standardized incidence and mortality in Germany, 1980 – 2004, ICD-10 C64 – 66, C68
Cases/deaths per 100,000 (European Standard)
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cases DCO casesless than 90% registration rate: casesat least 90% registration: 
Region Men Women
Crude rate % DCO Stand  rate* Crude rate % DCO Stand  rate*
Baden-Württemberg registry currently being developed
Bavaria 22.5 17 18.6 13.6 22 8.7
Berlin 18.5 31 16.5 10.5 33 7.0
Brandenburg 30.9 10 25.1 20.1 13 12.9
Bremen 27.0 9 20.4 14.9 9 9.3
Hamburg 17.8 6 15.3 11.4 5 7.3
Hesse (Darmstadt admin. dist.) 17.4 46 14.0 9.7 45 6.1
Mecklenburg-Western Pomerania 31.3 8 25.7 18.7 10 11.9
Lower Saxony 28.5 24 22.9 16.3 28 10.0
North Rhine-Westphalia (Münster admin. dist.) 22.2 9 18.7 12.5 11 8.1
Rhineland-Palatinate 22.5 17 17.8 14.6 19 9.2
Saarland 22.8 3 17.2 13.3 4 7.8
Saxony 28.8 10 21.5 19.6 14 11.1
Saxony-Anhalt 27.5 20 20.9 15.6 25 9.3
Schleswig-Holstein 24.7 17 19.3 12.9 25 8.0
Thuringia 30.9 16 24.5 20.6 16 12.6
Germany, estimated 26 3 3 21 3 15 4 4 9 9
                                                                                                      — at least 90% registration     —  less than 90% registration rate
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Figure 3 16 4
Registered age-standardized incidence in the regions of Germany, 2003 – 2004, ICD-10 C64 – 66, C68
New cases per 100,000 (European Standard)
Table 3 16 2
Registered incidence in the regions of Germany, 2003 – 2004, ICD-10 C64 – 66, C68
New cases per 100,000 (*European Standard)
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Trends
The marked increase in the incidence of blad-
der cancer in the 1970s and 1980s was probably 
based on changes in the histopathological crite-
ria for malignancy, according to which superficial 
papillary tumours of the urothelium were counted 
among invasive bladder cancer. Another change 
in these criteria in the early 1990s (in the opposite 
direction) therefore led to steeply declining inci-
dence rates of cancer. The incidence rates of blad-
der tumours according to our definition increased 
up to the early 1990s in both sexes, after which the 
trend reversed, most markedly in men. Altogether, 
the incidence rate is much higher in men. The 
mortality rate, too, has been falling for almost ten 
years, particularly in men.
Survival
The prognosis in the case of bladder cancer varies 
considerably depending on the stage of the dis-
ease at the time of diagnosis. Since most cases are 
discovered at the locally limited stage, because of 
the above-mentioned categorization, the average 
relative 5-year survival rate is about 70% among 
women and 76% among men. Of course, the rela-
tive 5-year survival rates fall considerably if only 
invasive carcinomas of the bladder are counted. 
The prospects of survival are slim if the cancer has 
already metastasized to the lymph nodes.
Prevalence
According to the latest estimates, about 28,750 
people in Germany develop a tumour of the blad-
der every year. Men are almost three times as fre-
quently affected as women. The bladder is one of 
the most common cancer sites in men, not least 
because our definition covers not only invasive 
(complete) and superficial (in situ) carcinomas, 
but also neoplasms of uncertain or unknown 
behaviour. The average age at diagnosis of bladder 
tumours is relatively high: 71 among men and 74 
among women. Virtually all malignant neoplasms 
of the bladder are carcinomas of the urothelium, 
which are also called transitional cell carcinomas 
and are frequently multi-focal (occurring in dif-
ferent places in the same organ at the same time). 
Squamous-cell carcinomas and adenocarcino-
mas of the bladder are much rarer. A distinction 
is made between flat and papillary (wart-shaped) 
growth forms.
Risk factors
Cigarette consumption is the main risk factor in 
the development of bladder cancer. Environmen-
tal tobacco smoke also increases the risk. Apart 
from tobacco consumption, exposure to certain 
chemicals (e.g. aromatic amines) is regarded as a 
risk. Even though either the known, most hazard-
ous working materials have been largely removed 
from the working processes of rubber, leather and 
textile processing and the chemical industry, or 
protective measures have meanwhile been intro-
duced in Europe, occupational bladder carcinomas 
still occur today because of the long latencies.
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Figure 3 17 1
Estimated age-specific incidence in Germany in 2004, ICD-10 C67, D09 0, D41 4
New cases per 100,000 by age groups
Figure 3 17 2
Age-standardized incidence rates in Germany in 2002 according to the RKI's 1980 – 2002 estimates,  
and in 2004 according to the RKI's 1980 – 2004 estimates, compared internationally, ICD-10 C67, D09 0, D41 4
Incidence per 100,000 (World Standard)
Source: Globocan estimate 2002, the RKI's 2002 and 2004 estimates for Germany
ICD-10 C67, D09.0, D41.4     Cancer in Germany
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Incidence Mortality Incidence  Mortality 
Men        Women
Age in years Men Women
Incidence Mortality Incidence Mortality
under 15 0.0 0.0 0.0 0.0
15 to under 35 0.0 0.0 0.0 0.0
35 to under 40 0.0 0.0 0.0 0.0
40 to under 45 6.0 0.4 5.6 0.3
45 to under 50 15.5 1.7 5.7 0.5
50 to under 55 38.2 2.8 11.9 0.8
55 to under 60 67.9 5.5 18.0 1.6
60 to under 65 101.1 9.4 24.8 2.4
65 to under 70 168.9 17.8 34.7 6.0
70 to under 75 244.6 35.0 56.9 9.8
75 to under 80 329.3 62.8 78.3 19.5
80 to under 85 385.5 113.2 74.1 32.6
85 and older 388.1 185.2 95.2 61.4
Crude rate 53.1 8.8 17.4 4.7
Stand. rate (European standard) 41.7 7.1 10.3 2.2
Cancer in Germany     Bladder
Table 3 17 1
Incidence and mortality by age group in Germany in 2004, ICD-10 C67, D09 0, D41 4
Cases/deaths per 100,000 by age groups
Figure 3 17 3
Age-standardized incidence and mortality in Germany, 1980 – 2004, ICD-10 C67, D09 0, D41 4
Cases/deaths per 100,000 (European Standard)
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Region Men Women
Crude rate % DCO Stand  rate* Crude rate % DCO Stand  rate*
Baden-Württemberg registry currently being developed
Bavaria 35.3 11 28.8 12.3 16 7.2
Berlin 31.7 19 29.0 15.0 25 8.8
Brandenburg 44.1 5 36.1 15.0 13 8.4
Bremen 60.7 3 45.3 23.5 1 11.5
Hamburg 35.8 3 29.5 14.2 6 8.2
Hesse (Darmstadt admin. dist.) 35.1 28 28.2 11.6 29 6.8
Mecklenburg-Western Pomerania 43.2 5 37.9 14.4 11 8.1
Lower Saxony 58.2 11 45.6 18.3 18 10.4
North Rhine-Westphalia (Münster admin. dist.) 45.7 3 38.3 16.7 6 10.0
Rhineland-Palatinate 44.0 11 33.7 15.5 19 8.9
Saarland 48.0 1 35.1 16.6 3 9.3
Saxony 44.6 9 32.8 16.4 14 7.9
Saxony-Anhalt 35.6 15 27.4 13.1 21 6.6
Schleswig-Holstein 53.1 8 41.0 18.2 12 10.4
Thuringia 37.3 9 29.5 12.2 14 6.7
Germany, estimated 53 2 2 42 4 17 6 4 10 4
                                                                                                      — at least 90% registration     —  less than 90% registration rate
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Figure 3 17 4
Registered age-standardized incidence in the regions of Germany, 2003 – 2004, ICD-10 C67, D09 0, D41 4
New cases per 100,000 (European Standard)
Table 3 17 2
Registered incidence in the regions of Germany, 2003 – 2004, ICD-10 C67, D09 0, D41 4
New cases per 100,000 (*European Standard)
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Trends
The mortality rates for both sexes have been fall-
ing continuously over the last 25 years. The inci-
dence rates among men rose until the mid-1990s 
and have remained at this level since then. By con-
trast, incidence rates among women are still rising 
continuously. 
Survival
The relative 5-year survival rate is slightly better 
among women (90%) than among men (87%) and 
much higher than ten years ago (77% and 67% 
respectively). The best survival prospects are asso-
ciated with papillary carcinoma, the typical thyroid 
carcinoma in young people. By contrast, survival 
prospects are quite bleak in the case of anaplastic 
thyroid carcinomas.
Prevalence
There are four types of thyroid cancer with differ-
ent clinical progressions and prognoses: 
(a)  papillary carcinomas (approx. 50%, typically 
affecting young adults), 
(b)  follicular carcinomas (20-30%, in which fre-
quency peaks in the 50-60 age group), 
(c)  anaplastic carcinomas (10%, predominantly 
affecting the elderly) and 
(d) medullary or C-cell carcinomas. 
The latter develop from special cells in the thyroid 
gland which regulate calcium metabolism.
Over 5,000 people in the Federal Repub-
lic develop thyroid cancer every year. With over 
3,500 new cases a year, women are much more 
frequently affected than men. The average age at 
onset is 54 among women and 57 among men, i.e. 
much younger in both cases than for most other 
cancers. In 2004 a total of 676 people, 445 of them 
women, died of this disease in Germany.
Risk factors
One confirmed risk factor is exposure to ionizing 
radiation, above all in childhood. Benign adeno-
mas of the thyroid gland and goitre diseases (the 
latter especially among people under the age of 50) 
are regarded as pre-existing diseases and increase 
cancer risk. Approximately a quarter of the rare 
medullary thyroid carcinomas occur as a family 
variant (multiple endocrine neoplasia type 2, or 
MEN 2) with an autosomal dominant inheritance 
pattern. In the meantime, a genetic component is 
also regarded as a probable risk factor in the case 
of non-medullary forms of the disease; hormonal 
and dietetic factors are also under discussion. The 
proportion of papillary and anaplastic carcinomas 
is regularly higher in regions of iodine deficiency. 
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Figure 3 18 1
Estimated age-specific incidence in Germany in 2004, ICD-10 C73
New cases per 100,000 by age groups
Figure 3 18 2
Age-standardized incidence rates in Germany in 2002 according to the RKI's 1980 – 2002 estimates,  
and in 2004 according to the RKI's 1980 – 2004 estimates, compared internationally, ICD-10 C73
Incidence per 100,000 (World Standard)
Source: Globocan estimate 2002, the RKI's 2002 and 2004 estimates for Germany
ICD-10 C73     Cancer in Germany
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Incidence Mortality Incidence  Mortality 
Men        Women
Age in years Men Women
Incidence Mortality Incidence Mortality
under 15 0.0 0.0 0.0 0.0
15 to under 35 1.5 0.0 3.5 0.0
35 to under 40 2.2 0.0 9.0 0.1
40 to under 45 3.5 0.2 11.9 0.2
45 to under 50 5.3 0.3 13.8 0.3
50 to under 55 6.3 0.4 14.4 0.3
55 to under 60 8.6 0.8 17.5 0.5
60 to under 65 7.5 0.9 13.5 1.0
65 to under 70 8.1 1.4 13.2 1.7
70 to under 75 8.2 2.3 12.0 3.3
75 to under 80 6.2 4.1 9.0 4.8
80 to under 85 3.2 5.1 6.5 7.2
85 and older 5.8 4.1 6.0 7.0
Crude rate 3.8 0.6 8.4 1.1
Stand. rate (European standard) 3.3 0.5 7.3 0.6
Cancer in Germany     Thyroid gland
Table 3 18 1
Incidence and mortality by age group in Germany in 2004, ICD-10 C73
Cases/deaths per 100,000 by age groups
Figure 3 18 3
Age-standardized incidence and mortality in Germany, 1980 – 2004, ICD-10 C73
Cases/deaths per 100,000 (European Standard)
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cases DCO casesless than 90% registration rate: casesat least 90% registration: 
       Men     Women
Region Men Women
Crude rate % DCO Stand  rate* Crude rate % DCO Stand  rate*
Baden-Württemberg registry currently being developed
Bavaria 4.5 8 3.9 9.8 5 8.8
Berlin 2.5 5 2.1 7.7 5 6.2
Brandenburg 4.2 0 3.6 10.2 0 8.6
Bremen 3.4 0 3.1 4.7 6 3.4
Hamburg 1.2 10 1.0 2.4 5 1.8
Hesse (Darmstadt admin. dist.) 1.5 43 1.3 2.5 38 1.9
Mecklenburg-Western Pomerania 2.7 0 2.3 8.7 1 7.4
Lower Saxony 2.8 10 2.4 6.1 9 5.0
Nord Rhine-Westphalia (Münster admin. dist.) 1.2 6 1.1 4.5 15 3.8
Rhineland-Palatinate 2.7 20 2.4 6.4 13 5.0
Saarland 2.5 0 2.0 7.5 2 6.5
Saxony 3.1 3 2.6 6.6 4 5.3
Saxony-Anhalt 3.5 7 2.8 10.0 9 8.0
Schleswig-Holstein 2.2 13 1.8 6.7 8 5.7
Thuringia 1.7 15 1.4 5.2 15 4.1
Germany, estimated 3 8 3 3 3 8 4 2 7 3
                                                                                                      — at least 90% registration     —  less than 90% registration rate
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Figure 3 18 4
Registered age-standardized incidence in the regions of Germany, 2003 – 2004, ICD-10 C73
New cases per 100,000 (European Standard)
Table 3 18 2
Registered incidence in the regions of Germany, 2003 – 2004, ICD-10 C73
New cases per 100,000 (*European Standard)
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Trends
Because the number of cases is small, incidence 
rates for Hodgkin's disease in Germany vary from 
year to year and from one registry to another. The 
overall incidence rates estimated for Germany 
reveal a consistently decreasing trend among men; 
the same trend was not recorded in women until 
the 1990s. This estimate involves uncertainties, 
however. Mortality fell markedly and continuously 
in both sexes during the observation period.
Survival
The prognosis for patients with Hodgkin's disease 
is very favourable. The relative 5-year survival rates 
are between 87% and 97% for men and women 
respectively. 
Prevalence
Hodgkin lymphoma, formerly known as lym-
phogranulomatosis, is distinguished from the 
non-Hodgkin lymphoma by the presence of micro-
scopic Sternberg-Reed giant cells in the bone 
marrow. An estimated 2,000 people per year are 
diagnosed with Hodgkin lymphoma in Germany. 
This number is relatively small and accounts for 
0.5% of all new cancer cases among men and 
women respectively. The average age at onset is 
very young, approx. 43 among men and 37 among 
women. A significant proportion of cases already 
occur in adolescence.
Risk factors
The risk factors for Hodgkin's disease have only 
been partly clarified up to now. As in the case of 
non-Hodgkin lymphomas, congenital and acquired 
characteristics of the immune system as well as 
viral infections are under discussion. Epstein-Barr 
viruses, the pathogens of Pfeiffer's glandular fever 
(infectious mononucleosis), and retroviruses (e.g. 
HTLV and HIV) are under discussion as possible 
contributory factors. Scientific interest is increas-
ingly focusing on hereditary factors or a genetic 
disposition for malignant lymphomas. Children, 
brothers and sisters of patients with Hodgkin's 
disease have a markedly higher risk of developing 
the disease themselves.
3 19  Hodgkin's disease
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Figure 3 19 1
Estimated age-specific incidence in Germany in 2004, ICD-10 C81
New cases per 100,000 by age groups
Figure 3 19 2
Age-standardized incidence rates in Germany in 2002 according to the RKI's 1980 – 2002 estimates,  
and in 2004 according to the RKI's 1980 – 2004 estimates, compared internationally, ICD-10 C81
Incidence per 100,000 (World Standard)
Source: Globocan estimate 2002, the RKI's 2002 and 2004 estimates for Germany
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Incidence Mortality Incidence  Mortality 
Men        Women
Age in years Men Women
Incidence Mortality Incidence Mortality
under 15 1.5 0.0 1.3 0.0
15 to under 35 3.1 0.2 3.6 0.1
35 to under 40 2.4 0.2 2.7 0.2
40 to under 45 2.1 0.2 1.5 0.1
45 to under 50 2.3 0.4 1.6 0.1
50 to under 55 2.4 0.4 1.2 0.3
55 to under 60 3.6 0.4 1.5 0.4
60 to under 65 2.9 0.7 1.7 0.2
65 to under 70 3.1 1.3 2.6 0.8
70 to under 75 3.2 2.0 1.5 1.0
75 to under 80 3.2 2.4 3.3 1.5
80 to under 85 3.1 2.4 2.1 1.9
85 and older 0.8 3.0 1.5 1.4
Crude rate 2.6 0.5 2.2 0.4
Stand. rate (European standard) 2.5 0.4 2.2 0.2
Cancer in Germany     Hodgkin's disease
Table 3 19 1
Incidence and mortality by age group in Germany in 2004, ICD-10 C81
Cases/deaths per 100,000 by age groups
Figure 3 19 3
Age-standardized incidence and mortality in Germany, 1980 – 2004, ICD-10 C81
Cases/deaths per 100,000 (European Standard)
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Region Men Women
Crude rate % DCO Stand  rate* Crude rate % DCO Stand  rate*
Baden-Württemberg registry currently being developed
Bavaria 2.5 12 2.4 2.1 11 2.0
Berlin 2.4 6 2.2 1.9 12 1.9
Brandenburg 2.6 9 2.4 2.3 7 2.2
Bremen 2.2 7 1.9 1.5 0 1.6
Hamburg 2.1 0 2.0 2.7 0 2.3
Hesse (Darmstadt admin. dist.) 1.8 54 1.6 1.6 48 1.2
Mecklenburg-Western Pomerania 1.7 7 1.5 1.8 10 1.5
Lower Saxony 3.2 15 3.0 2.0 26 1.8
North Rhine-Westphalia (Münster admin. dist.) 2.2 0 2.1 1.5 2 1.4
Rhineland-Palatinate 2.2 20 2.0 1.8 12 1.7
Saarland 2.9 0 2.8 1.8 0 1.8
Saxony 2.1 7 2.0 1.8 9 1.7
Saxony-Anhalt 2.3 11 2.1 2.0 17 1.8
Schleswig-Holstein 4.3 5 4.0 2.5 8 2.4
Thuringia 2.4 7 2.1 1.8 9 1.7
Germany, estimated 2 6 1 2 5 2 3 0 2 2
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Figure 3 19 4
Registered age-standardized incidence in the regions of Germany, 2003 – 2004, ICD-10 C81
New cases per 100,000 (European Standard)
Table 3 19 2
Registered incidence in the regions of Germany, 2003 – 2004, ICD-10 C81
New cases per 100,000 (*European Standard)
94
nant lymphomas. In addition, smoking seems to 
play a role in the case of highly aggressive forms. 
Trends
The estimated age-standardized incidence rates 
in Germany rose at the same rate in both sexes 
between 1980 and 1995 – parallel to the develop-
ment in other European countries. There are signs 
of a plateau or slight fall since the turn of the mil-
lennium. The mortality rates have developed in 
a similar way, although the rise was less steep. It 
should be pointed out, however, that there were 
different competing classification systems for lym-
phomas with corresponding delimitation prob-
lems during this period, so that the aggregation to 
non-Hodgkin lymphomas seems to make sense. 
There are also delimitation problems with chronic 
lymphatic leukaemia, which makes it more diffi-
cult to interpret the incidence rates. 
Survival
The relative overall 5-year survival rate in the case 
of non-Hodgkin lymphomas amounts to 62% in 
men and 66% in women.
Prevalence
Several different lymphoma types are subsumed 
under the term "non-Hodgkin lymphoma". In 
other words, non-Hodgkin lymphomas represent 
a very heterogeneous group in terms of their mor-
phological classification. The annual number of 
new cases in Germany is about 6,800 among men 
and 6,100 among women. Overall, they account 
for 2.9% of new cancer cases for both sexes. The 
average age at onset among men is 65, i.e. four 
years under the average age for all cancer sites. 
On average, women develop the disease at 70, one 
year later than the figure for all sites.
Risk factors
In the group of non-Hodgkin lymphomas, little 
can be said about risk factors that is valid for all 
forms. In most cases it is not possible to establish 
a cause/effect relationship. Insufficient training 
of the immune system in childhood might possi-
bly influence the risk. However, in view of contra-
dictory results, the so-called "hygiene hypothesis" 
cannot be regarded as proven. Viral infections also 
contribute to the development of these diseases, 
although the extent of their contribution and the 
role of possible co-factors cannot be assessed. 
There is a confirmed causal association between 
an infection with the Epstein Barr virus (EBV, the 
pathogen of Pfeiffer's glandular fever or infec-
tious mononucleosis) and Burkitt's lymphoma, 
which occurs predominantly in Africa. Clusters 
of T-cell lymphomas are observed in the context 
of infections with the human T-cell leukaemia 
virus HTLV-1. A chronic inflammation of the gas-
tric mucosa (stomach lining) with the bacterium 
Helicobacter pylori (which also causes stomach 
ulcers) seems to increase the risk of developing a 
local lymphoma of the gastric mucosa (MALT lym-
phoma). Furthermore, occupational and industrial 
exposure to heavy metals, certain organic solvents, 
herbicides, insecticides (based on organic phos-
phoric acid esters) and fungicides are under dis-
cussion as causal factors; however, it is very rare 
that they can be substantiated in a patient's case 
history. Radioactive radiation can trigger malig-
3 20  Non-Hodgkin lymphoma
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Figure 3 20 1
Estimated age-specific incidence in Germany in 2004, ICD-10 C82 – 85
New cases per 100,000 by age groups
Figure 3 20 2
Age-standardized incidence rates in Germany in 2002 according to the RKI's 1980 – 2002 estimates,  
and in 2004 according to the RKI's 1980 – 2004 estimates, compared internationally, ICD-10 C82 – 85
Incidence per 100,000 (World Standard)
Source: Globocan estimate 2002, the RKI's 2002 and 2004 estimates for Germany
ICD-10 C82 – 85     Cancer in Germany
96























Incidence Mortality Incidence  Mortality 
Men        Women
Age in years Men Women
Incidence Mortality Incidence Mortality
under 15 1.5 0.0 0.4 0.2
15 to under 35 3.2 0.4 1.6 0.3
35 to under 40 6.4 0.9 4.1 0.7
40 to under 45 8.2 1.3 5.7 0.5
45 to under 50 10.8 2.0 6.3 1.3
50 to under 55 20.2 4.5 13.4 2.9
55 to under 60 28.2 7.2 19.4 4.9
60 to under 65 31.5 11.1 25.3 6.7
65 to under 70 44.4 17.0 32.2 11.0
70 to under 75 54.1 27.6 45.8 19.7
75 to under 80 74.3 42.7 47.9 28.2
80 to under 85 70.4 58.6 53.2 42.1
85 and older 74.4 68.3 44.3 40.1
Crude rate 16.8 6.7 14.4 6.5
Stand. rate (European standard) 14.0 5.4 9.6 3.5
Cancer in Germany     Non-Hodgkin lymphoma
Table 3 20 1
Incidence and mortality by age group in Germany in 2004, ICD-10 C82 – 85
Cases/deaths per 100,000 by age groups
Figure 3 20 3
Age-standardized incidence and mortality in Germany, 1980 – 2004, ICD-10 C82 – 85
Cases/deaths per 100,000 (European Standard)
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cases DCO casesless than 90% registration rate: casesat least 90% registration: 
Region Men Women
Crude rate % DCO Stand  rate* Crude rate % DCO Stand  rate*
Baden-Württemberg registry currently being developed
Bavaria 14.4 18 12.2 12.9 21 8.9
Berlin 13.9 17 12.4 12.9 25 8.8
Brandenburg 15.9 10 13.4 13.6 14 8.5
Bremen 17.5 6 13.5 17.1 11 10.4
Hamburg 12.5 4 10.6 13.0 4 9.1
Hesse (Darmstadt admin. dist.) 11.9 49 9.7 10.7 44 6.7
Mecklenburg-Western Pomerania 15.6 7 13.5 17.2 6 11.5
Lower Saxony 20.3 22 16.4 18.2 26 11.6
North Rhine-Westphalia (Münster admin. dist.) 13.7 9 11.8 11.6 10 7.8
Rhineland-Palatinate 15.0 23 12.0 12.5 25 7.7
Saarland 18.9 2 15.5 17.7 2 11.0
Saxony 14.9 13 11.5 14.4 15 8.4
Saxony-Anhalt 15.2 17 12.0 14.8 20 9.3
Schleswig-Holstein 19.7 13 16.0 18.6 15 11.9
Thuringia 15.3 10 12.3 15.0 12 8.9
Germany, estimated 16 8 1 14 2 14 5 2 9 8
                                                                                                      — at least 90% registration     —  less than 90% registration rate
ICD-10 C82 – 85     Cancer in Germany
Figure 3 20 4
Registered age-standardized incidence in the regions of Germany, 2003 – 2004, ICD-10 C82 – 85
New cases per 100,000 (European Standard)
Table 3 20 2
Registered incidence in the regions of Germany, 2003 – 2004, ICD-10 C82 – 85
New cases per 100,000 (*European Standard)
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Trends
The incidence rates rose in the 1980s – markedly 
among men, less markedly among women. How-
ever, rates have been falling significantly among 
men since the early 1990s and less markedly 
among women since the mid-1990s. The mor-
tality rates have been declining among men and 
women since the early 1980s. However, the delimi-
tation problem between chronic lymphatic leukae-
mia and non-Hodgkin lymphomas must be taken 
into account when evaluating developments over 
time. 
Survival
The relative 5-year survival rates for leukaemias 
are 43% among men and 38% among women. 
The fact that, in this new edition, the survival rates 
were only calculated for over-15-year-olds certainly 
contributed to the decrease in survival rates com-
pared to the 5th edition published in 2006. The 
survival prospects of children are much better than 
those of adults (see section 4).
Prevalence
Leukaemias originate in the bone marrow and are 
classified according to acute and chronic progres-
sion forms and the different cell types affected. The 
main groups – acute lymphatic leukaemia (ALL), 
acute myeloid leukaemia (AML), chronic myeloid 
leukaemia (CML) and chronic lymphatic leukae-
mia (CLL) – differ substantially in terms of epide-
miology, disease biology and prognosis. It should 
be noted in particular that, based on findings of 
molecular biology, chronic lymphatic leukaemias 
can also be classified as low-risk lymphomas with 
a leukaemic progression. This blurs the distinc-
tion between leukaemias and non-Hodgkin lym-
phomas. About 9,100 people in Germany (approx. 
4,800 men and 4,300 women) are diagnosed with 
a form of leukaemia every year. That is 2.1% of all 
new cancer cases in both sexes. The average age at 
diagnosis of the disease is 67 among men and 70 
among women. While chronic forms of leukaemia 
only occur in adults, ALL is the most common can-
cer in children. AML occurs at all ages, but reaches 
its frequency peak among elderly people.
Risk factors
Ionizing radiation, cytostatic drugs and various 
chemicals such as benzene are known to be triggers 
of acute leukaemias, although it is comparatively 
rare that this can really be substantiated. There is 
also discussion on whether insufficient training of 
the immune system in childhood might contribute 
to an increase in the risk. Rare genetic modifica-
tions can increase the risk of leukaemia. The influ-
ence of viruses is under discussion but has not 
been unequivocally verified. An association with 
exposure to low-frequency electromagnetic fields 
has not been proven up to now. The causes of 
chronic leukaemias, the most common leukaemic 
diseases in adults, are largely unknown. Research 
is currently being carried out into (acquired or con-
genital) genetic modifications, which might possi-
bly contribute to an increased risk.
3 21  Leukaemias
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Figure 3 21 1
Estimated age-specific incidence in Germany in 2004, ICD-10 C91 – 95
New cases per 100,000 by age groups
Figure 3 21 2
Age-standardized incidence rates in Germany in 2002 according to the RKI's 1980 – 2002 estimates,  
and in 2004 according to the RKI's 1980 – 2004 estimates, compared internationally, ICD-10 C91 – 95
Incidence per 100,000 (World Standard)
Source: Globocan estimate 2002, the RKI's 2002 and 2004 estimates for Germany
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Incidence Mortality Incidence  Mortality 
Men        Women
Age in years Men Women
Incidence Mortality Incidence Mortality
under 15 3.4 0.7 4.3 0.5
15 to under 35 2.7 0.9 1.6 0.8
35 to under 40 3.8 1.0 2.5 0.9
40 to under 45 5.2 1.6 2.8 1.1
45 to under 50 5.3 2.7 4.7 2.1
50 to under 55 8.5 4.3 7.8 3.2
55 to under 60 16.1 7.4 11.1 5.5
60 to under 65 22.1 13.8 14.5 8.1
65 to under 70 28.1 23.0 20.7 13.4
70 to under 75 43.4 40.2 24.1 20.6
75 to under 80 60.1 60.2 28.2 32.5
80 to under 85 59.7 83.2 36.9 45.1
85 and older 66.6 103.5 59.7 58.8
Crude rate 11.9 9.2 10.2 7.9
Stand. rate (European standard) 10.1 7.4 7.1 4.4
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Table 3 21 1
Incidence and mortality by age group in Germany in 2004, ICD-10 C91 – 95
Cases/deaths per 100,000 by age groups
Figure 3 21 3
Age-standardized incidence and mortality in Germany, 1980 – 2004, ICD-10 C91 – 95
Cases/deaths per 100,000 (European Standard)
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cases DCO casesless than 90% registration rate: casesat least 90% registration: 
Region Men Women
Crude rate % DCO Stand  rate* Crude rate % DCO Stand  rate*
Baden-Württemberg registry currently being developed
Bavaria 12.3 38 10.5 10.4 45 6.9
Berlin 11.5 30 11.1 10.7 45 7.7
Brandenburg 14.7 22 13.3 12.7 32 9.0
Bremen 12.5 24 9.5 11.0 23 6.5
Hamburg 11.6 7 9.8 10.6 12 7.2
Hesse (Darmstadt admin. dist.) 10.2 73 8.2 8.8 74 4.9
Mecklenburg-Western Pomerania 13.4 13 11.6 10.5 16 7.2
Lower Saxony 13.9 30 11.4 11.8 38 7.5
North Rhine-Westphalia (Münster admin. dist.) 11.4 23 10.3 8.8 23 6.8
Rhineland-Palatinate 12.6 37 10.1 11.2 46 6.7
Saarland 12.7 14 10.4 10.7 10 6.8
Saxony 14.2 26 11.1 13.2 31 7.5
Saxony-Anhalt 15.5 36 12.7 12.4 38 7.8
Schleswig-Holstein 16.6 29 13.5 13.6 36 9.0
Thuringia 15.9 28 13.0 12.6 27 7.1
Germany, estimated 12 1 6 10 3 10 3 8 7 2
                                                                                                      — at least 90% registration     —  less than 90% registration rate
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Figure 3 21 4
Registered age-standardized incidence in the regions of Germany, 2003 – 2004, ICD-10 C91 – 95
New cases per 100,000 (European Standard)
Table 3 21 2
Registered incidence in the regions of Germany, 2003 – 2004, ICD-10 C91 – 95
New cases per 100,000 (*European Standard)
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joint cancer registry (GKR) of Berlin, Branden-
burg, Mecklenburg-Western Pomerania, Saxony-
Anhalt, Saxony and Thuringia. The current data 
basis consists of over 41,000 cancer cases.
Incidence of childhood cancers in Germany
About 1,800 cases are newly diagnosed every 
year in Germany. With an overall population of 
approx. 13 million children under the age of 15, 
this means an annual incidence of about 14 per 
100,000 children in this age group. The likeli-
hood that a newborn child will develop a malig-
nant disease within the first 15 years of its life is 
224:100,000 (0.2%). In other words, a malignant 
cancer disease is diagnosed in approx. one in 500 
children up to their 15th birthday. 
Range of diagnoses
The pattern of cancer diagnoses in children is 
completely different from that of adults. For 
example, children are mostly affected by embryo-
nal tumours (neuroblastomas, retinoblastomas, 
nephroblastomas, medulloblastomas, embryonic 
rhabdomyosarcomas or germ-cell tumours); car-
cinomas, by contrast, are very rare in childhood 
(less than 2% of all malignant diseases). The larg-
est diagnostic groups are leukaemias (34.1%), 
CNS tumours (22.1%) and lymphomas (11.8%). 
The German Childhood Cancer Registry (DKKR) 
has been based at the Institute of Medical Biosta-
tistics, Epidemiology and Informatics at the 
Johannes Gutenberg University, Mainz, since 
beginning its work in 1980. Close cooperation 
with the Society for Paediatric Oncology and Hae-
matology (GPOH) and the associated hospitals 
was already part of the DKKR's original concep-
tion. This is a characteristic feature of the registry 
which cannot be easily applied to adult oncology. 
A nationwide, population-based cancer registry 
with a high level of data quality and a degree of 
completeness of over 95% has been built up, cov-
ering the entire Federal Republic. The DKKR thus 
meets international standards for population-
based cancer registries. Tumours of the central 
nervous system (CNS tumours) are an exception 
here; completeness in this field is slightly lower. 
A further characteristic of the DKKR is that it has 
implemented an active, open-end, long-term fol-
low-up system which continues long into adult-
hood. In this way the registry also provides the 
basis for research into long-term effects, second-
ary tumours, and for studies with long-term sur-
vivors in general.
The registry population comprises children 
who are diagnosed with a malignant disease or 
a histologically benign brain tumour before their 
15th birthday and are part of the resident popu-
lation of the Federal Republic of Germany when 
diagnosed. Cancer cases in eastern Germany have 
been included since 1991 in cooperation with the 
4  Cancer in children
Figure 4 1
Cancer in children 
Determined for the period 1997 – 2006
Lymphomas  11.8 %  
Leukaemias  34.1 %  
CNS tumours  22.1 %  
Peripheral neural cell tumours  7.8 %  
Soft tissue (sarkome)  6.2 %
Kidney tumours  5.6 %  
Other Diagnoses  4.7 %  
Bone tumours  4.4 %  
Germ-cell tumours  3.2 %  
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Leukaemias
Leukaemias make up more than a third of all 
cancers among the under-15s. The most com-
mon single diagnosis overall is acute lymphatic 
leukaemia (ALL, 27.0%). It occurs more than 
twice as frequently among children under the 
age of four as in the other age groups. 4.8% 
of all childhood malignancies are acute mye-
loid leukaemias (AML). AML is most common 
Overall cancer incidence in children under the 
age of five is about twice as high as in the 5 – 14 
age group. The median age at onset among the 
under-15s is at five years eight months. Boys are 
diagnosed with cancer 1.2 times more frequently 
than girls. 
Figure 4 2
New cases by age and gender, all childhood malignancies 
Number of cases per 100,000 by age group, determined for the period 1997 – 2006
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New cases by age and gender, childhood acute lymphatic leukaemia (ALL)
Number of cases per 100,000 by age group, determined for the period 1997 – 2006
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Figure 4 5
Trends in the incidence of childhood leukaemias 
Number of cases per 100,000 (age-standardized), including eastern Germany since 1991







acute lymphatic leukaemia (ALL) acute myeloid leukaemia (AML)
pesticides) is quite small after all, even if an 
association with leukaemias in childhood can-
not be ruled out. A number of clues have in the 
meantime strengthened hypotheses that assign 
a central role to infectious pathogens in the 
development of leukaemias in childhood. Espe-
cially children with an insufficiently modulated 
immune system in babyhood can have a higher 
risk of developing leukaemia.
in children under the age of two. The survival 
rates for AML are markedly lower than for ALL. 
The causes of leukaemias in childhood remain 
largely uncertain, even today. For a long time 
environmental influences were suspected of 
causing childhood leukaemias. In the mean-
time it has been shown that the number of cases 
caused by most environmental factors (low-dose 
ionizing radiation, non-ionizing radiation and 
Figure 4 4
Trends in the incidence of selected diagnostic groups and for all childhood malignancies 
Number of cases per 100,000 (age-standardized), including eastern Germany since 1991
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pected between lymphomas and ionizing radia-
tion; this has not, however, been substantiated. 
Other common malignant diseases
Other common malignant diseases in childhood 
include neuroblastomas (nerve-cell tumours), 
Wilms' tumours or nephroblastomas (kidney 
tumours), germ-cell tumours, bone tumours and 
rhabdomyosarcomas (tumours of the skeletal 
musculature). Among these malignancies, the 
prognosis for children with nephroblastoma or a 
germ-cell tumour is much more favourable than 
for the others.
Survival
Children with cancer make up fewer than 1% 
of all cancer patients. However, malignant neo-
plasms are the second most common cause of 
death among children. Fortunately, the survival 
rates have improved dramatically over the last 30 
years thanks to significantly more differentiated 
diagnostics and the use of multimodal therapy 
CNS tumours
The most common single diagnoses among CNS 
tumours are astrocytomas (total: 10.2%), intrac-
ranial and intraspinal embryonal tumours (5.0%) 
and ependymomas (2.2%). The increase in the 
incidence of CNS tumours observed in a number 
of western countries over the past decades may be 
connected with general changes in environmen-
tal factors and related exposure. For example, a 
number of epidemiological studies are looking 
into the possible influence of ionizing radiation, 
electromagnetic fields, pesticides, the mother's 
diet and genetic aspects.
Lymphomas
The most common lymphomas are non-Hodg-
kin lymphomas (NHL, total: 5.5%) and Hodg-
kin's disease (4.9%). The chances of survival 
with Hodgkin's disease are among the best in 
paediatric oncology. Children with congenital or 
acquired immunodeficiency and those who have 
had immunosuppressive therapy are at increased 
risk of developing NHL. An association is sus-
Table 4.1
Number of cancer cases
Percentage incidence and survival rates, determined for the period 1997 – 2006
Cancer sites Incidence* Survival rate in percent
after 3 years after 5 years after 10 years
Hodgkin lymphomas 0.7 97 97 95
Germ-cell tumours 0.5 95 94 92
Lymphatic leukaemias 4.1 91 88 85
Nephroblastomas 0.9 91 90 89
Non-Hodgkin lymphomas 0.8 88 87 86
Neuroblastomas and ganglioneuroblastomas 1.3 83 78 75
Osteosarcomas 0.3 82 73 68
Astrocytomas 1.5 79 77 73
Rhabdomyosarcomas 0.5 78 74 71
Ewing's tumours & related bone sarcomas 0.3 74 69 65
Intracranial & intraspinal embryonal tumours 0.8 68 61 52
Acute myeloid leukaemias 0.7 65 62 60
All malignancies 15.0 84 81 77
* related to 100,000 children under the age of 15, age-standardized to the west German population in 1987
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concepts. In the early 1980s the chances of chil-
dren with cancer still being alive five years after 
diagnosis were 67%; this figure has risen to 80% 
in the meantime. Looking at all patients of the 
registry population who were diagnosed between 
1997 and 2006 and followed up, the overall 
chance of survival is 81% after five years, 77% 
after ten years, and 76% after 15 years. 
The encouraging increase in the number of long-
term survivors is increasingly focusing attention 
on the long-term observation of former paediat-
ric cancer patients. The DKKR provides an ideal 
data base for carrying out studies with long-term 
survivors. As the above figures show, it is already 
possible to provide information on long-term sur-
vival (after 5, 10 or 15 years) and to estimate the 
risk of developing a second malignancy after can-
cer in childhood. Examples of further research 
possibilities include the incidence of other long-
term effects, such as the possible effects of ther-
apy on fertility, and studies examining the health 
risks of the descendants of fathers and mothers 
who had cancer in childhood. About 12,000 of the 
more than 25,000 patients currently known to 
be alive have been under observation by the reg-
istry for at least twelve years. Over half of these 
patients are over 18 years old in the meantime, 
and are thus, in principle, available for studies 
with long-term survivors.
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point of contact for all the population-based can-
cer registries on issues involving more than one 
(or all) states.
In its charter, the GEKID has set itself the follow-
ing tasks:
to be the point of contact both for national and  ▶
international cooperation partners and for the 
interested public,
to provide information on the status of cancer  ▶
registration in Germany and to explain the aims 
of population-based cancer registration,
to engage in joint information activities and  ▶
thus help the individual cancer registries 
achieve and maintain complete registration,
to define standards on content as a basis for  ▶
the comparability of population-based cancer 
registries,
to coordinate tasks involving all the registries  ▶
and to foster contacts with clinical tumour 
documentation,
to initiate joint research activities, ▶
to promote the scientific use of the population- ▶
based cancer registries, and
to use the data for the purpose of quality assur- ▶
ance in oncological care.
Association of Population-based Cancer Registries 
in Germany (Gesellschaft der epidemiologischen 
Krebsregister in Deutschland e.V.)
In April 2004 the "Arbeitsgemeinschaft Bevöl-
kerungsbezogener Krebsregister in Deutschland" 
(Working Group of Population-based Cancer Reg-
istries in Germany) was turned into a registered, 
non-profit-making association: the "Gesellschaft 
der epidemiologischen Krebsregister in Deutsch-
land e.V." (Association of Population-based Cancer 
Registries in Germany), or GEKID.
The members of the GEKID include not only 
all Germany's population-based cancer registries, 
but also a tumour centre and interested scientists 
working in the field of cancer epidemiology. In 
the field of cancer control, the GEKID cooperates 
closely with the Federal Ministry of Health (BMG) 
and the Federal Cancer Surveillance Unit based at 
the Robert Koch Institute (RKI).
The newly formed association's primary task 
is to standardize as far as possible the content 
and methodology of cancer registration, despite 
the differences in legislation between the federal 
states. The comparability of results from the can-
cer registries can only be assured by nationwide 
cooperation. Furthermore, GEKID acts as a joint 
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Association of Population-Based Cancer Registries in Germany
Information on the GEKID can be obtained on the 
Internet at www.gekid.de, the respective regional 
member registries, and the Board of Directors (see 
address section).
Contacts for the Association of Population-based 
Cancer Registries in Germany (Gesellschaft der 
epidemiologischen Krebsregister in Deutschland 
e.V., GEKID) (see address section):
PD Dr Alexander Katalinic (Chair of GEKID, 
 Schleswig-Holstein Cancer Registry) 
Dr Stefan Hentschel (1st Vice-chair, Hamburg 
 Cancer Registry)
Dr Bettina Eisinger (2nd Vice-chair, Joint Cancer 
 Registry)
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Addresses
Bevölkerungsbezogenes Krebsregister Bayern (Bavaria Population-based Cancer Registry) 
Östliche Stadtmauerstrasse 30a 
91054 Erlangen  Telephone: 09131/853 60 35 (R) Telefax: 09131/853 60 40 (R)
  0911/378 67 38 (V)  0911/378 76 19 (V)
 Email:  krebsregister@ekr.med.uni-erlangen.de
 Internet:  www.krebsregister-bayern.de
Gemeinsames Krebsregister der Länder Berlin, Brandenburg, Mecklenburg-Vorpommern, Sachsen-Anhalt und 
der Freistaaten Sachsen und Thüringen (Joint Cancer Registry of Berlin, Brandenburg, Mecklenburg-Western 
Pomerania, Saxony-Anhalt, Saxony and Thuringia), GKR
Brodauer Strasse 16–22
12621 Berlin Telephone: 030/56 58 14 01 (R) Telefax: 030/56 58 14 44 (R)
  030/56 58 13 15 (V)  030/56 58 13 33 (V)
 Email: registerstelle@gkr.berlin.de (R)
  vertrauensstelle@gkr.berlin.de (V)
 Internet: www.krebsregister-berlin.de
Krebsregister des Landes Bremen (Bremen Cancer Registry)
Bremer Institut für Präventionsforschung und Sozialmedizin 
(Bremen Institute for Prevention Research and Social Medicine), BIPS
Linzer Strasse 10
28359 Bremen Telephone: 0421/595 96 49 (R) Telefax: 0421/595 96 68 (R)
  0421/595 96 44 (V)
 Email:  krebsregister@bips.uni-bremen.de (R)
  vbkr.kvhb@t-online.de (V)
 Internet: www.krebsregister.bremen.de
Hamburgisches Krebsregister (Hamburg Cancer Registry) 
Behörde für Soziales, Familie, Gesundheit und Verbraucherschutz 
(State Ministry of Social Affairs, Family, Health and Consumer Protection)
Billstrasse 80a
20539 Hamburg Telephone: 040/428 37 22 11 Telefax: 040/428 37 26 55
  Email:  HamburgischesKrebsregister@bsg.hamburg.de
 Internet: www.krebsregister.hamburg.de
Krebsregister Hessen (Hesse Cancer Registry)
Vertrauensstelle des Krebsregisters bei der Landesärztekammer Hessen 
(Data Collection Office of the Cancer Registry at the Hesse State Medical Council) 
Im Vogelsgesang 3
60488 Frankfurt/Main Telephone: 02771/32 06 39 (R) Telefax: 02771/366 71 (R)
   069/789 04 50 (V)   069/78 90 45 29 (V)
 Email: vertrauensstelle@laekh.de
 Internet: www.laekh.de
Epidemiologisches Krebsregister Niedersachsen (Lower Saxony Population-based Cancer Registry)
OFFIS CARE GmbH
Industriestrasse 9
26121 Oldenburg  Telephone: 0441/361 05 60 (R) Telefax: 0441/36 10 56 10 (R)
  0511/450 53 56 (V)   0511/450 51 32 (V)
 Email: registerstelle@krebsregister-niedersachsen.de (R)
  vertrauensstelle.ekn@nlga.niedersachsen.de (V)
 Internet:  www.krebsregister-niedersachsen.de
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Epidemiologisches Krebsregister NRW gGmbH 
(North Rhine-Westphalia Population-based Cancer Registry)
Robert-Koch-Strasse 40
48149 Münster  Telephone: 0251/835 85 71 Telefax: 0251/835 85 77
 Email: info@krebsregister.nrw.de
 Internet: www.krebsregister.nrw.de
Krebsregister Rheinland-Pfalz (Rhineland-Palatinate Cancer Registry)
Institut für Medizinische Biometrie, Epidemiologie und Informatik 
(Institute of Medical Biostatistics, Epidemiology and Informatics), IMBEI
55101 Mainz  Telephone: 06131/17 67 10 (R) Telefax: 06131/17 47 51 86 (R)
  06131/17 30 02 (V)  06131/17 34 29 (V)
 Email: krebsregister@imbei.uni-mainz.de
 Internet: www.krebsregister-rheinland-pfalz.de
Epidemiologisches Krebsregister Saarland (Saarland Population-based Cancer Registry)
Ministerium für Justiz, Arbeit, Gesundheit und Soziales 
(Ministry of Justice, Labour, Health and Social Affairs) MJAGS
Virchowstrasse 7 
66119 Saarbrücken Telephone: 0681/501 59 82 (R) Telefax: 0681/501 59 98 (R)
  0681/501 58 05 (V)
 Email: krebsregister@gbe-ekr.saarland.de
 Internet: www.krebsregister.saarland.de
Krebsregister Schleswig-Holstein (Schleswig-Holstein Cancer Registry)
Institut für Krebsepidemiologie e.V. (Institute of Cancer Epidemiology) 
Beckergrube 43 –47 
23552 Lübeck Telephone: 0451/799 25 50 (R) Telefax: 0451/799 25 51 (R)
  04551/80 31 04 (V)
 Email:  info@krebsregister-sh.de
 Internet:  www.krebsregister-sh.de
Deutsches Kinderkrebsregister (German Childhood Cancer Registry) 
Institut für Medizinische Biometrie, Epidemiologie und Informatik 
(Institute of Medical Biostatistics, Epidemiology and Informatics), IMBEI
55101 Mainz  Telephone: 06131/17 31 11 Telefax: 06131/17 29 68
 Email:  kinderkrebsregister@imbei.uni-mainz.de
 Internet:  www.kinderkrebsregister.de
R = Registry Office (data analysis) V = Data Collection Office (confidentiality assured)
Further contacts:
Federal Cancer Surveillance Unit at the Robert Koch Institute
Seestrasse 10 
13353 Berlin Telephone: 030/18 754 33 10 Telefax: 030/18 754 35 13
  Email: DachdokumentationKrebs@rki.de
 Internet: www.rki.de
Bundesministerium für Gesundheit (Federal Ministry of Health)
53107 Bonn 
Referat 311 Telephone: 0228/99 441 15 10 Telefax: 0228/99 441 49 31
Referat 315 Telephone: 0228/99 441 31 08 Telefax: 0228/99 441 49 38
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Glossary
adenocarcinoma malignant epithelial neoplasm (cancer) of the glandular epithelium (mucosa) (e.g. of the 
digestive tract)
adenoma benign epithelial neoplasm of the glandular epithelium (e.g. of the digestive tract)
anaplastic undifferentiated, so that the original tissue is no longer recognizable
asymptomatic no symptoms and no abnormality detected 
autosomal dominant 
inheritance pattern
sex-independent inheritance pattern in which a characteristic is expressed if one of the 
two existing genes is affected 
Barrett's oesophagus persistent defect after healing of a reflux disease (see below) in which the surface is trans-
formed (from a squamous epithelium into a columnar epithelium)
carcinoma malignant epithelial neoplasm (cancer) 
case-control study epidemiological study comparing certain characteristics in patients ("cases") and non-
patients ("controls") 
climacteric concerning the menopause in women, phase of hormonal transition until menstruation 
stops
climacteric disorder disorder during the menopause in women (e.g. hot flushes)
cluster accumulation of events (e.g. of cancer cases) in a certain place or period 
co-factors factors that can increase the effect of a risk factor 
cohort study epidemiological study in which a certain group of people is observed over a longer period 
of time
colonoscopy internal examination of the large intestine using an inserted endoscope 
colorectal carcinoma malignant epithelial neoplasm (cancer) of the colon and rectum
congenital naevus mole (birthmark) present from birth 
DCO 'death certificate only', i.e. based solely on information from the death certificate
diabetes mellitus chronic disorder of carbohydrate metabolism 
disposition congenital or acquired susceptibility to diseases
dysplastic naevus deformed, irregularly outlined and pigmented naevus with an uneven surface 
embryonic period  16th to 60th day of pregnancy 
endometrial relating to the endometrium (lining of the uterus)
endometrial cancer malignant neoplasm of the uterus lining 




population-based cancer registry that collects data on all the cancer cases that occur in a 
certain population
epidemiology science dealing with the description and analysis of diseases in a population
epithel(ium) cell layers covering internal (e.g. lungs or intestines) and external (e.g. skin) body surfaces 
evaluation analysis and assessment of processes, e.g. in the field of health 
exposure being subjected to damaging influences (e.g. air pollution) 
familial adenomatous 
polyposis (FAP)
inheritable colorectal disease in which the mucosal surface of the colon is covered with 
small adenomatous polyps
genetic predisposition inherited tendency or susceptibility to certain diseases
incidence frequency of cases, how often a disease is contracted (annual number of new cases per 
100,000 of the population)
indicator a factor that makes it possible to measure a certain condition or event (e.g. the 
completeness of registration)
intracranial situated in the skull
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intraspinal situated in the spinal cord canal
invasive proliferating into the surrounding tissue; a criterion of a malignant neoplasm
log-linear model statistical method of analysis
long-term follow-up long-term observation of a certain group of people
lymphocyte blood cell of the immune system
malignant melanoma malignant tumour of the pigment-forming cells (melanocytes) usually in the skin, the 
mucous membranes, the choroid of the inner eye or the meninges, which cover the brain
MALT lymphoma mucosa associated lymphoid tissue: lymphoma that develops in lymphocyte-rich tissue 
(e.g. in the mucous membranes of the gastrointestinal tract) 




carcinoma of the C-cells in the thyroid gland which produce excessive amounts of 
calcitonin (which regulate calcium levels in the blood) 
Ménétrier's disease disorder in which the gastric mucosal folds (gastric lining) are enlarged
metastasizing intermittent propagation of tumours to distant tissues
mortality death rate (annual number of deaths per 100,000 of the population)
neoplasm tumour, new growth
obesity corpulence, severe overweight
oncological concerning cancer
PAP smear microscopic examination of a smear taken from the mouth of the uterus used in cancer 
screening, named after Dr George PAPanicolaou
papillary wart-shaped
pernicious anaemia anaemia caused by a deficiency of cobalamin (vitamin B12)
polycyclic aromatic 
hydrocarbons
PAH, group of organic compounds consisting of at least two interconnected benzene 
rings 
polycystic ovaries enlarged ovaries containing several cavities filled with liquid (cysts) 
polynomial an algebraic expression consisting of one or more summed terms, each term consisting 
of a constant multiplier and one or more variables raised to integral powers.
postmenopause time after the last menstruation (menopause)
postnatal after birth
precancerous defined potential preliminary stage of a carcinoma
PSA prostate-specific antigen; a test for PSA in the blood is used in screening for prostate 
cancer
radon radioactive inert gas formed by the radioactive decay of radium; can accumulate in badly 
ventilated rooms
reflux disease / 
refluxoesophagitis
backing up of the stomach contents into the oesophagus, leading to an inflammation of 
the mucous membrane




malignant epithelial neoplasm of superficial squamous cells (e.g. of the lung or the skin)
stomach polyps protuberances (usually stalk-like swelling) of the stomach lining (gastric mucosa)
subfertility reduced fertility or ability to conceive 
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The brochure “Cancer in Germany” is published jointly every 
two years by the Association of Population-based Cancer 
Registries in Germany (Gesellschaft der epidemiologischen 
Krebsregister in Deutschland e.V., GEKID) and the Robert 
Koch Institute (RKI). This sixth edition has a new design and 
is being published for the first time as part of a series of  
reports within the framework of Federal Health Reporting 
(German abbreviation: GBE). It contains information on the 
total number of new cancer cases in Germany diagnosed 
between 1980 and 2004, and on selected individual cancer 
sites, each of which is succinctly described and clearly pre-
sented (with information on incidence and mortality rates, 
risk factors, trends and survival). The RKI’s current estimates 
are based on data from population-based cancer registries in 
Germany that provide sufficiently complete coverage. The  
estimate for 2004 is 436,500 new cancer cases (230,500 
men, 206,000 women). This means the number of new can-
cer cases was approx. 12,000 higher in 2004 than in 2002, 
when the previous estimate ended. The total number of  
cases among women remained unchanged compared to 
2002. Most of the additional cases in 2004 were men with 
prostate cancer, the most common cancer among men with 
approx. 58,500 cases. As in previous estimates, the most 
common form of cancer among women was breast cancer 
with approx. 57,000 new cases. A total of 208,800 people 
died of cancer in Germany in 2004 compared to 209,900 
in 2002. The survival prospects of patients with prostate 
or breast cancer have improved to such an extent that the 
number of people dying from these cancers is now decreas-
ing. 11,200 men died of prostate cancer and 17,600 women 
of breast cancer in 2004 – which is 200 fewer respectively 
than two years earlier. Information on cancer in children is 
provided by the Children’s Cancer Registry in Mainz in a 
separate section of this brochure.
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